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 Over the past 20 years, a major shift in the type 2 diabetes mellitus (T2DM) epidemic has 
occurred.  Even though the etiology of T2DM has not yet been discovered, insulin resistance, 
associated with plasma lipid and lipoprotein abnormalities, has shed light to this chronic disease.  
According to the Centers for Disease Control and Prevention (CDC), 97% of individuals with 
diabetes have one or more plasma lipid abnormalities, including decreased high density 
lipoprotein (HDL) cholesterol, a predominance of small dense low density lipoprotein (LDL) 
particles and hypertriglyceridemia (HTG).  Diabetic patients often develop hyperlipidemia at the 
early stage of the disease and often before the onset of overt hyperglycemia (diabetes).  It is also 
well established that the prevalence of T2DM in the United States is associated with increased 
prevalence of obesity.  The therapeutic plan for T2DM begins with modifications of lifestyle, such 
as physical activity, changes in diet, weight loss, and smoking cessation (2005 American 
Diabetes Association clinical guidelines).  This is often concomitant with pharmacological therapy.  
Statins, fibrates, niacin, and thiazolidinediones are commonly used to treat dyslipidemia 
associated with insulin resistance and T2DM.   
 The TALLYHO/Jng (TH) mouse strain is a newly established polygenic inbred model for 
T2DM that shows obesity, hyperinsulinemia, insulin resistance, hyperglycemia (males), and 
dyslipidemia with the early onset of HTG.  Previous work in this laboratory has revealed that 
insulin resistance is profoundly associated with HTG in TH male mice.  The aim of the present 
study was to characterize the pathogenesis of HTG in TH mice and test the hypothesis that 
lowering the plasma lipid levels will improve insulin resistance and glucose metabolism in this 
model.   
 In vivo studies indicated that the very low density lipoprotein-triglyceride (VLDL-TG) 
production from liver was not significantly altered in TH mice compared to control B6 mice.  On 
the other hand, TH mice showed a significantly increased residual percentage of injected [3H] TG-
labeled VLDL at all sampling times compared to B6 mice, indicating slower VLDL-TG clearance 
rate in TH mice.  In support of the slowed VLDL-TG clearance rate in TH mice, we found 
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evidence of hepatic over-expression of the Apo C-III gene in TH mice compared to the age- and 
sex-matched B6 mice.  Finally, addition of a drug bezafibrate, known to selectively lower plasma 
lipid levels without changing plasma glucose levels, to the diet significantly reduced plasma TG 
concentrations in both B6 and TH mice.  Despite the remarkable decrease in plasma TG levels, 
either glucose tolerance or uptake was not improved in TH mice.   
In summary, the HTG appears to be due to a defect in triglyceride-rich lipoprotein 
clearance in TH mice, and overproduction of Apo C-III may be in part involved in the 
pathogenesis.  Further, the HTG is not likely the primary defect for the impaired insulin action in 
TH mice.  These results shed light on the mechanism underlying the HTG in obese type 2 
diabetic TH mice, which may contribute to understanding the pathophysiology of diabetic HTG in 
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CHAPTER 1: INTRODUCTION 
 
 It is well established that the prevalence of diabetes has increased worldwide (1).  
Between 1980 and 2004, the number of individuals with diabetes increased from 5.8 million to 
14.6 million, and almost 40% of people aged 65 years or older have diabetes (2).  While 20.8 
million Americans have diabetes, 6.2 million cases go undiagnosed.  According to Gerberding of 
the CDC, “new evidence shows that 1 in 3 Americans born in 2000 will develop diabetes 
sometime during their lifetime” (3).  Type 2 diabetes mellitus (T2DM) is the most common form of 
human diabetes, accounting for approximately 90% of cases (4).  Researchers believe that the 
rising prevalence of diabetes worldwide is associated with increases in the prevalence of obesity 
and sedentary lifestyle (5).  
Diabetes mellitus (DM) can be defined as a group of diseases characterized by high 
levels of blood glucose resulting from defects in insulin production, insulin action, or both (6).  
Further, 97% of adults with diabetes have one or more lipid alterations characterized by 
increased fasting triglyceride (TG), small dense low-density lipoprotein (LDL), and low high-
density lipoprotein (HDL) cholesterol (1, 7).  Diabetic patients often develop hypertriglyceridemia 
(HTG) at the early stage of the disease, before the onset of overt hyperglycemia.  Recent 
evidence has demonstrated that HTG is an independent risk factor for coronary heart disease, 
the prominent cause of diabetic deaths (8).   
 Genetic animal models have been valuable resources for T2DM research, and few 
polygenic rodent models, where multiple genes are involved in the development of the disease, 
have been developed (9).  These models include the Goto-Kakizaki (GK), Otsuka Long-Evans 
Tokushima Fatty (OLETF) rats, Spontaneously Diabetic Torii (SDT) rats, the Nagoya-Shibata-
Yasuda (NSY) mice, the Tsumura-Suzuki-Obese-Diabetes (TSOD) mice (10) and the NZO/NON 
F1 hybrid mice (11).   
 The TALLYHO/Jng (TH) mouse strain is a newly established polygenic inbred model for 
T2DM, derived from two deviant male mice showing polyuria and glucosuria in an outbred colony 
(12).  TH mice are characterized by various physiological features, including obesity, 
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hyperinsulinemia, insulin resistance, hyperglycemia (males), and dyslipidemia associated with 
increased TG, free fatty acids, and cholesterol levels (12).  Our longitudinal study has revealed 
that insulin resistance is profoundly associated with HTG in TH male mice, and the HTG 
preceded overt diabetes in this model.   
The aim of the present study was to characterize the pathogenesis of HTG in TH mice 
and test the hypothesis that lowering the plasma lipid levels will improve insulin resistance and 
glucose metabolism in this model.  This study will shed light on the mechanism underlying the 
HTG in obese type 2 diabetic TH mice and contribute to understanding the pathophysiology of 



































CHAPTER 2: LITERATURE REVIEW 
 
I.  DIABETES: THE NEW EPIDEMIC 
  According to the Center for Disease Control and Prevention (CDC), diabetes is the 6th 
leading cause of associated death in the United States (US).  In 2002 alone, the number of 
deaths resulting from diabetes included 73,249 (13).  Approximately 800,000 new cases of 
diabetes are detected every year, or 2,200 per day (14, 15).  While 20.8 million Americans have 
diabetes, 6.2 million cases go undiagnosed.  According to Gerberding of the CDC, “new evidence 
shows that 1 in 3 Americans born in 2000 will develop diabetes sometime during their lifetime” (3).  
Researchers believe that the rising prevalence of diabetes is associated with increases in the 
prevalence of obesity and sedentary lifestyle (5).  The National Health and Nutrition Examination 
Survey (NHANES), using measured heights and weights, shows that from 1999-2002 an 
estimated 65% of U.S. adults are either overweight or obese.  This suggests that the prevalence 
is 16% higher than the results of the age-adjusted overweight estimates in the NHANES III survey 
that was completed from 1988-1994 (16).  According to the American Dietetic Association (ADA), 
about 80% of people with type 2 diabetes mellitus (T2DM) are overweight or obese (17).  
Diabetes mellitus can be defined as a group of diseases characterized by high levels of blood 
glucose resulting from defects in insulin production, insulin action, or both (6).  Overweight and 
obesity have an adverse relationship with insulin secretion and sensitivity (18).    
 T2DM accounts for over 90% of the cases of diabetes (4).  Unlike type 1A diabetes that is 
caused by an autoimmune defect in the function of pancreatic beta cells, T2DM has normal 
pancreas functions, but the peripheral tissues do not recognize glucose as being available for 
uptake (19).  Hodge et al claims that by 2020, approximately 250 million people worldwide will be 
affected with T2DM (20).  This disease usually affects middle aged and older adults, individuals 
who are overweight, and have a family history of T2DM (21).  T2DM is associated with an 
increased risk for mortality and morbidity (22).  Life expectancy is shorter in middle aged 
individuals with T2DM because T2DM is a risk factor for coronary heart disease (CHD) (23). 
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 Between 1980 and 2004, the number of individuals with diabetes increased from 5.8 
million to 14.6 million, and almost 40% of people aged 65 years or older have diabetes (2).   
According to the CDC National Diabetes Fact Sheet, the number of individuals with diabetes 
aged 20 or older in the US is approximately 20.6 million in 2005.  This statistic represents 9.6% of 
the population.  Approximately 10.9 million men have diabetes in this age group while women 
make up 9.7 million of this age group (2). The prevalence of diagnosed diabetes among people 
under the age of 20 is also alarming.  In 2005 approximately 176,500 people in the United States 
under 20 years of age were diagnosed with diabetes.  This statistic signifies 0.22% of this 
population (2).  In addition, about 1 in every 400 to 600 children and adolescents has type 1 
diabetes.  T2DM is also a growing problem for this age group, but data for these trends are 
unavailable (2).    
 Race and ethnicity also play a role in defining the total prevalence of diabetes among 
people aged 20 years or older.  In 2005, Non-Hispanic whites made up 13.1 million of this 
population in the US, and Non-Hispanic blacks included 3.2 million of the population.  
Approximately 2.5 million Hispanic/Latino Americans have or had diabetes in 2005.  Last, there 
are 99,500 American Indians and Alaska Natives who receive care from the Indian Health Service 
(IHS).  This signifies that 12.8% of American Indians and Alaska Natives aged 20 years or older 
who receive care from IHS have diabetes (2).  
 In 2002, the annual health care costs associated with diabetes is approximately $132 
billion dollars in the US.  This includes both direct and indirect costs.  Directs costs include $92 
billion, which are due to medical care, insulin, and drugs.  Indirect costs are around $40 billion, 
which are due to disability, work loss, or premature mortality (2).  
II. DIABETIC DYSLIPIDEMIA   
 According to the CDC, 97% of adults with diabetes have one or more lipid abnormalities, 
such as decreased high density lipoprotein (HDL) cholesterol, a predominance of small dense low 
density lipoprotein (LDL) particles and increased triglyceride (TG) levels (7, 24).  Adult Treatment 
Panel III (ATP III) and ADA have established the optimal targets of lipid values.  The LDL 
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cholesterol concentration should be less than 2.6 mmol/L (< 100 mg/dL); TG less than 1.7 mmol/L 
(< 150 mg/dL) and HDL greater than 1.15 mmol/L (> 45 mg/dL) for men, and for women HDL 
cholesterol should be greater than 1.42 mmol/L (> 55 mg/dL).  According to the NHANES III, 85% 
of patients with T2DM had values of LDL cholesterol greater than 2.6 mmol/L, 42% had TG levels 
greater than 2.3mmol/L, and 62% of people had levels of HDL cholesterol less than 1.15 mmol/L.  
Another study conveyed similar results (25).   
A survey was conducted on 65,651 people with T2DM from the Basque Country in Spain.  
These results indicated that 91% of the participants had LDL cholesterol values greater than 2.58 
mmol/L, 38.8% had TG values greater than 1.7mmol/L, and 20.8% of the subjects had HDL 
cholesterol values less than 1.03 mmol/L.  These findings clearly suggest that there is a problem 
with blood lipid concentrations in T2DM patients (25).   
 It is widely known that a reduced HDL concentration puts individuals at increased risk for 
coronary heart disease (CHD) (5).  HDL particles serve many roles in protecting the heart, such 
as promotion of cellular cholesterol efflux and direct anti-oxidative and anti-inflammatory 
properties.  Furthermore, low HDL concentrations are frequently associated with increased TG 
levels, and this association has been positively correlated with an increased risk of CHD.  In the 
Quebec Cardiovascular Study, it was discovered that HDL2  particles have more cardioprotective 
effects of high HDL cholesterol levels than HDL3 particles (7).  The subclasses of HDL were 
determined by first measuring the HDL-cholesterol in the supernatant fraction after precipitation of 
apoprotein-B containing lipoproteins with heparin/manganese chloride.  Then using a 4% solution 
of low molecular weight dextran sulfate, HDL2 was precipitated from the HDL fraction.  The 
cholesterol concentration of HDL3 was then determined and HDL2 was derived by subtracting 
HDL3 from total HDL cholesterol concentrations.  Concentrations of HDL cholesterol subfractions 
may be altered by numerous factors, such as obesity, exercise, and diet (26).  However, one 
limitation in this study is that the association may depend on the specific population being studied.  
For example, in the Department of Veteran’s Affairs HDL Intervention Trial (VA-HIT), it was noted 
that reduced CHD events in men treated with gemfibrozil were linked with levels of HDL3.  
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Therefore, increased levels of HDL2 and HDL3 particles may both serve as protective effects 
against heart disease (7).     
 People with T2DM and CHD often have small HDL particles.  Hyperinsulinemia and 
hypertriglyceridemia (HTG) are independently associated with low levels of HDL2 and small HDL 
particle size (7). Epidemiologic studies suggest a correlation between plasma TG levels and the 
risk of CHD.  A meta-analysis of 17 population-based prospective studies showed that for each 1 
mmol/L increase in plasma TG there is a 32% increase in CHD risk for men and a 76% increase 
in risk for women (27).  Effects of triglyceride rich lipoproteins (TRL) such as intermediate density 
lipoprotein (IDL) and remnant particles may explain for this independent contribution of plasma 
TG levels to CHD risk.  These studies prove that the characteristic dyslipidemia, associated with 
insulin resistance and T2DM, is positively correlated with an increased risk for cardiovascular 
disease (CVD) (7). 
III.  PEROXISOME PROLIFERATOR ACTIVAED RECEPTORS (PPARS) 
Classifying the molecular mechanisms of the transducer proteins, which play a role with 
the metabolic and anabolic pathways, is very important for understanding the energy 
homeostasis in the human body.  This allows added insight in the development of new 
therapeutic agents for the treatment of chronic metabolic disorders including atherosclerosis and 
diabetes.  Peroxisome proliferator activated receptors (PPARs) are transcriptional factors that are 
part of the ligand-activated nuclear receptor superfamily.  These receptors were identified in the 
1990s in rodent models and received their name after peroxisome proliferation.  Natural fatty 
acids and the fibrate class of lowering lipid drugs are known to activate PPARs.  PPARs play a 
major role in controlling the expression of numerous genes that are involved in lipid and glucose 
metabolism (28).   
PPARs’ structure is very similar to other nuclear receptors, such as steroid or thyroid 
receptors.  They have an NH2 terminal region accompanied with a ligand independent 
transactivation domain.  This is usually followed by a DNA binding domain, and at the other end, 
COOH terminus, a ligand and dimerization domain and a ligand dependent activation domain.  
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Three major types of PPARs have been discovered thus far, including PPAR-α, PPAR-δ, and 
PPAR-γ, with each having their own unique characteristics (28).    
PPAR-α 
 PPAR-α is highly expressed in the liver, heart, kidney cortex, and skeletal muscles (22).  
Activation of PPAR-α has a major effect on lipid oxidation.  For example, PPAR-α stimulates the 
expression of fatty acid transport proteins (FATP) and long chain acyl-CoA synthase in the liver.  
Furthermore, enzymes that play a role in peroxisomal beta-oxidation, such as acyl-CoA oxidase, 
are direct targets for PPAR-α.  Whereas peroxisomal beta-oxidation does not provide energy, it 
does shorten very long-chain fatty acids, and this way mitochondrial beta-oxidation can occur.  
Peroxisomal beta-oxidation also oxidizes molecules, including eicosanoids and xenobiotics (24).   
 PPAR-α also has other effects.  For example, in mitochondrial beta-oxidation, carnitine 
palmitoly transferase I (CPTI), which is the rate limiting enzyme, is known to be a marker for 
PPAR-α, although this is much in debate, whether or not CPT1 expression is controlled by 
PPAR-α.  Activation of PPAR-α also induces the expression of medium chain acyl CoA 
dehydrogenase.  This is an important step in mitochondrial beta-oxidation.  PPAR-α also 
stimulates the expression of 3-Hydroxy-3-methyl glutaryl CoA (HMG-CoA) synthase, which is 
involved in ketone body synthesis.    
 Activity of pyruvate dehydrogenase kinase 4 (PDK4) is also affected by PPAR-α.  PDK4 
is a kinase that phosphorylates and inactivates pyruvate dehydrogenase (PDH).  If the PDH 
complex is activated, glucose carbons will be oxidized.  On the other hand, if PDH is inactivated 
in skeletal muscle, the glucose carbons will be used for lactate synthesis.  During times of 
starvation or diabetes, which is associated with a high fatty acid (FA) availability, PPAR-α may be 
activated, thus having increased PDK4 expression, inactivating PDH and glucose carbon sparing.   
The PPAR-α null mice model has helped to establish the physiological role of PPAR-α.  
Based on this model, numerous enzymes involved in hepatic fatty acid activation, peroxisomal 
oxidation, and mitochondrial oxidation have been established as markers for PPAR-α (24).  
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PPAR-α is also known to have a role in cardiac lipid catabolism.  For instance, FA oxidative 
capacity is decreased in heart tissue of these null mice.  Myocardial damage and fibrosis may 
also occur.  However, in skeletal muscles, the problem with FA oxidation is less serious because 
PDK4 acts normally.  Research has demonstrated that PPAR-δ is able to make up for this defect 
(24).  PPAR-α null mice model also has a major role in the adaptation to starvation.  During 
starvation, these mice have a fatty liver mainly due to lower fatty acid oxidation capacity.  Ketone 
bodies are also low because the enzyme HMG-CoA synthase is degraded.  Glucose metabolism 
can be severely affected because starvation in these mice leads to definite hypoglycemia.  
Several reasons show for this.  For example, since gluconeogenesis needs a high rate of FA 
oxidation to supply energy and cofactors, glucose production in the liver may be reduced.  Also 
since ketone bodies are not present, glucose will have to be used (24).   
PPAR-α also plays a role in insulin sensitivity.  When PPAR-α is activated in obese 
Zucker rats or lipoatrophic models, insulin sensitivity does improve (24).  It is also known that 
intracellular fatty acids create a problem for insulin-stimulated glucose metabolism (24).  If PPAR-
α is activated, however, oxidation of FA should increase, thereby lowering the tissue content of 
lipids and reducing lipotoxicity (24).   
The fibrate, such as bezafibrate (BF), is a lipid lowering agent that is a known activator 
for PPAR-α (29).  Both animal and human studies have shown protective effects of fibrates 
against HTG, hyperglycemia, and insulin resistance.  However, changes in a patient’s lipid levels 
will depend on pretreatment lipoprotein status and the effectiveness of the type of fibrate used.  In 
most studies, the obvious effect of fibrates is a decrease in plasma TRL levels.  Furthermore, LDL 
cholesterol levels usually decrease in patients who have increased baseline plasma 
concentrations.  HDL cholesterol levels generally increase when baseline plasma concentrations 
are low (30).   
There are five major mechanisms that explain how the treatment with fibrates can affect 
lipoprotein status (30).   
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1. Induction of lipoprotein lipolysis.  Increased TRL lipolysis could indicate that there were 
changes in LPL activity or TRL were more available for lipolysis by LPL due to a 
reduction of TRL of Apolipoprotein C-III (Apo C-III).  
2. Induction of hepatic FA uptake and reduction of hepatic TG production.  Studies 
performed in rodents show that fibrates increase FA uptake and the conversion to acyl-
CoA by liver.  This is due to the stimulation of FA transporter (FATP) and acyl-CoA 
synthetase (ACS) activity.   
3. Increased removal of LDL particles.  Treatment with fibrate helps LDL have a higher 
affinity for the LDL receptor, which are therefore broken down faster.   
4. Decreased plasma TRL.  A decrease in plasma TRL levels may lower neutral lipid 
exchange between VLDL and HDL.   
5. Increase in HDL production and the stimulation of reverse cholesterol transport.  Fibrate 
treatment may increase the production of Apo A-I and Apo A-II gene expression in liver, 
therefore contributing to the increase of HDL levels and a more effective reverse 
cholesterol transport (30).              
  BF is an effective nonselective activator for PPAR-α.  Taniguchi et al (31)  investigated 
the effects of BF treatment on plasma glucose, insulin, total cholesterol, and TG levels.  The 
subjects included non-obese Japanese type 2 diabetic patients whose age ranged from 42-75.  
With regard to TG levels, BF treatment reduced serum TG levels significantly.  Fasting insulin and 
fasting glucose both decreased significantly after BF treatment.  While HDL cholesterol 
significantly increased, total cholesterol levels were unchanged throughout the study.  BF 
treatment also improved insulin resistance and fasting insulin levels without affecting insulin 
secretion in the study subjects.  
Jia et al (29) examined the effects of BF on diabetic Otsuka Long-Evans Tokushima Fatty 
(OLETF) rats and control Long Evans Tokushima Otsuka (LETO) rats.  Administration of BF 
significantly decreased serum TG levels in the OLETF rats.  BF treatment, however, exhibited 
very minor effects on improving insulin sensitivity in OLETF rats.  
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PPAR-γ   
 Ligands for PPAR-γ are unsaturated fatty acids such as oleate, linoleate, 
eicosapentaenoic, and arachidonic acid, and a prostanoid named 15-deoxy-δ-12, 14-
prostaglandin J2 (24).  Thiazolidinediones (TZD) are also included in this group (24).  
Lipid storage and insulin sensitivity are regulated by PPAR-γ.  When PPAR-γ is activated, 
it induces the storage of FAs into mature adipocytes through several ways: LPL stimulation; 
intracellular FA transport stimulation; FAs activation via acyl-CoA synthase and FA esterification 
(24).   
PPAR-γ also plays a role in regulation of insulin sensitivity.  PPAR-γ transgenic mice were 
resistant to high fat diet induced insulin resistance (24).  TZDs are strong compounds that reduce 
hyperglycemia, hyperinsulinemia, and HTG, characteristics that are often seen in patients with 
T2DM and in animal models of T2DM.  TZDs role is to improve insulin sensitivity of tissues, 
especially in skeletal muscle.  PPAR-γ is high in skeletal muscle, which is the most important 
tissue in insulin-dependent glucose utilization.  It is demonstrated that the involvement of PPAR-γ 
in insulin sensitivity comes from the fact that TZDs are potent and specific activators of PPAR-γ 
(24).     
When PPAR-γ is activated, it also controls the expression of products produced by the 
adipocyte.   It does this by reducing leptin expression and activating adiponectin expression, a 
protein involved in insulin sensitivity.  PPAR-γ also stimulates the secretion of a particular protein 
called PPAR-γ angiopoietin-related gene (PGAR).  These proteins play a positive role in vascular 
development (24).    
 Although PPAR-γ agonists, TZDs are said to have beneficial effects on insulin sensitivity, 
there are problems and unresolved questions dealing with this issue.  For example, diabetic or 
obese animals treated with TZDs induce adipocyte proliferation and weight gain  (24).  This might 
be due to PPAR-γ being a prominent adipogenic transcription factor.  However, increasing the 
number of adipocytes is not adequate to explain the weight gain.  There must be disequilibrium 
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between energy intake and expense.  In animal models, most treatment with TZDs shows a noted 
food intake increase.  Only a slight weight gain could be seen in humans, and this weight was 
observed in subcutaneous adipose tissue.  It is unknown why the excessive weight gain was 
seen in this particular area (24).    
 Roles of PPARs are better understood because of ligands such as TZDs or fibrates, but 
their activation in physiological and pathophysiological circumstances is still unclear.  This might 
explain for the problems and inconsistency that was discussed above. 
IV. PATHOGENESIS OF DIABETIC DYSLIPIDEMIA  
 The etiology of atherogenic dyslipidemia of diabetes is generally associated with altered 
metabolism of TRLs.  TRLs include particles derived from the intestine (chylomicrons (CM) and 
their remnants) containing Apolipoprotein B (Apo B) 100 and the liver VLDL.  Apo B 48 and Apo B 
100 separate particles derived from exogenous and endogenous pathways that fall within the 
same density range.  On the other hand, the liver produces a range of Apo B 100 comprised of 
particles that differ in size and density from large VLDL to LDL.  Large buoyant VLDL 1 particles 
and small dense VLDL 2 particles make up the two primary subclasses of VLDL.  The first group, 
large buoyant VLDL 1 particles seem to play a role in determining plasma TG and Apo B 100 in 
subjects who have normal lipid levels but also in patients who may have high TG levels.  
Furthermore, high VLDL 1 TG is the deciding factor of plasma TG levels in T2DM as well (25).  
 Intermediate-density lipoproteins (IDL) make up VLDL and CM and are found to be 
atherogenic in humans and in a number of animal models (7).  CMs are produced in the intestinal 
lumen after fat is digested.  They are the largest of the lipoproteins and are rich in TG.  Their 
function is to transport lipids from the liver to the peripheral tissue.  VLDL is a lipoprotein similar to 
that of a CM, which contains a high concentration of TG.  LDL is known to be atherogenic, 
carrying the majority of the cholesterol in the blood and supplying cholesterol to the cells.  On the 
other hand, high levels of HDL are correlated with decreased risk for CHD.  The function of HDL 
is to facilitate the transfer of cholesterol from atherogenic lipoproteins and peripheral tissues to 
the liver (32).   
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 An increased production of small dense LDL particles may also be a consequence from 
increased hepatic production and/or delayed clearance from plasma of large VLDL.  There have 
been seven different LDL subspecies reported.  They all differ in their metabolic behavior and 
physiological roles.  There is an association between plasma VLDL levels and increased density 
and decreased size of LDL.  Furthermore, the LDL size and density are negatively associated 
with plasma levels of HDL particularly the HDL2 subclass.  A number of steps, such as lipolysis, 
play a role in the intricate process involving small dense LDL particles and larger VLDL 
precursors of LDL.  Also, a larger accumulation of small dense LDL particles may result from the 
interaction involving cholesteryl ester transfer protein and the hydrolysis of TG and plasma 
lipoproteins by hepatic lipase (HL) (7).   
 The make-up of HDL particles is very diverse and includes several subclasses that vary 
in diameter and density.  Classes include small dense HDL3c, HDL3b, and HDL3a and large HDL2a 
and HDL2b.  It is suggested that HDL is reduced in patients with T2DM and who are insulin 
resistant.  Although the mechanism is unclear, it seems to result from the increased transfer of 
cholesterol from HDL to TRLs, including reciprocal transfer of TG to HDL.  The reduced HDL 
levels in plasma observed in patients with T2DM arise from the reductions in the HDL2b subclass 
or from the increases seen in the smaller dense HDL3c and HDL3b subclasses. (7).    
 In T2DM, insulin resistance occurs when muscle, fat, and liver cells do not respond to the 
action of insulin properly.  The pancreas has trouble keeping up with the body's need for insulin, 
and as a result high levels of insulin are shown in the bloodstream (33).  In patients with T2DM 
and who are also insulin resistant, there is an increased efflux of free fatty acid (FFA) from 
adipose tissue and impaired insulin mediated skeletal muscle uptake of FFA increase FFA flux to 
the liver (34).  Epidemiologic studies have also shown a relationship between plasma FFA levels 
and insulin resistance.  In individuals who are insulin resistant, FFA in the form of TG are 
accumulated in non-adipose tissues including the muscle, liver, heart, and pancreas.   
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Lipoprotein Lipase (LPL) 
 Lipoprotein lipase (LPL) is one of the most important enzymes involved in the metabolism 
of TRLs.  LPL is normally synthesized in most extrahepatic tissues, mainly in adipose tissue and 
muscle (35).  LPL regulates plasma lipoprotein levels through the hydrolysis of TG in CM and 
VLDL at the luminal side of the endothelium.  FFAs are generated through this process and are 
used as an energy source in the muscle or stored as fat in adipose tissue.  LPL also catalyzes the 
hydrolysis of HDL phospholipids and TG (36).  Moreover, LPL plays a role in the hepatic 
clearance of TRL by regulating receptor mediated uptake of atherogenic LP particles.  Therefore, 
LPL is said to have anti-atherogenic effects.  On the other hand, LPL located on the 
subendothelially side may have pro-atherogenic effects by increasing oxidative susceptibility of 
LDL to help with TRL uptake by macrophages.  This action may increase the chances of foam 
cell formation, which is a characteristic of atherogenesis (37).      
 Diabetes is linked with a deficiency in LPL and the development of HTG.  Most studies 
involving the regulation of LPL have been performed in control rats, streptozotocin-induced 
diabetic rats, and diabetic rats treated chronically or with a single dose of insulin.  Tavangar et al 
demonstrated that diabetes decreased LPL activity in adipose tissue by decreasing 
immunoreactive LPL protein and the steady-state levels of LPL mRNA.  However the main factor 
is that diabetes reduces the catalytic activity of LPL (38).   
 LPL is important during regulation of plasma TG.  During the fed state, a high adipose 
LPL activity along with low activity in the muscle may result in the preferential uptake of 
hydrolyzed TG by adipose tissue for storage.  However, during fasting, high muscle activity and 
low adipose LPL activity will make plasma TG the leading energy source.  Insulin plays an 
important role in the nutritional regulation of LPL.  Under a number of physiological states, there 
is a strong association between plasma insulin levels and LPL activity in adipose tissue (38).  
Even so, there are other factors that need to be considered that deal with the relationship 
between insulin levels and muscle LPL activity because this relationship is not easily understood 
(38).   
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 Numerous factors play a role in the regulation of LPL.  For instance, insulin deficiency, as 
seen in diabetes, can result in an increase in plasma TG and FFA levels.  As a result, FFA levels 
in the liver will lead to an increase in VLDL synthesis.  However, the VLDL synthetic rates 
improve in prolonged diabetes.  Also because of the decrease in LPL activity a potential problem 
may be detected in the removal of TRL from plasma.  When comparing the physical state of the 
lipoproteins between diabetic animals and normal animals, the TRL from diabetic animals were 
cleared more slowly.  Insulin, however, can help correct the diabetic dyslipidemia that occurs from 
insulin deficiency.  The regulation of LPL in diabetes seems to play a major role in the defect of 
removing TRL from plasma.  In this case, LPL activity in the adipose tissue is low and is not 
influenced by the absence of insulin.  However, the impact that diabetes has on muscle tissue is 
variable.  In cases that study diabetic heart and skeletal muscle, LPL activity can be noted as 
unchanged, increased, or decreased (38).   
The Metabolism of Lipids 
 Apolipoproteins are proteins that combine with a lipid to form a lipoprotein.  They are 
grouped into four classes: A, B, C, and E and a fifth class D but is now considered part of A  (39).  
While these proteins have the ability to bind lipids, each class of apolipoproteins has different 
features.  For instance, apolipoproteins can form a relationship with all the different density 
classes of lipoproteins (LP) and sometimes act as ligands that influence the interaction of LP with 
cell surface receptors.  Furthermore, apolipoproteins play a role in lipid metabolism by serving as 
cofactors for enzymes.  There are nine major apolipoproteins, including Apo A-I, Apo A-II, Apo A-
IV, Apo B-48, Apo B-100, Apo C-I, Apo C-II, Apo C-III, and Apo-E (40).  These proteins are found 
in humans, and their genes are isolated on at least three different chromosomes.  Gene 
expression of apolipoproteins is regulated by development, hormones, and diet (41).   
 LPs are macromolecular complexes containing plasma lipids, especially cholesterol and 
TG, in the plasma.  They also contain hundreds of proteins.  These proteins act as a coat for 
particles that are packed with lipids.  TG and cholesteryl esters are present mainly in the particle 
core whereas the unesterified cholesterol and phospholipids (PL) are located on the surface (42).  
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There are different kinds of LPs, including CM, VLDL, IDL, LDL and HDL, found in the blood 
classified accordingly to their density.  Also, each LP affects the risk for heart disease in a 
different way.  Abnormalities in plasma lipids and LPs levels contribute to the risk for CAD.  
However, mutations in the major genes involved in LP metabolism may also contribute to CHD.  
Genetic studies are providing new insights into disease mechanisms, and these studies, along 
with biochemical approaches, are giving way to new treatments (43).   
Apolipoprotein C-III (Apo C-III) 
 Apo C-III is mainly synthesized in the liver but also in the intestine (44).  Apo C-III is a 8.8 
kDa glycoprotein and a 79 amino acid protein (45).  Apo C-III is found in human plasma and 
distributed among TRLs, CM and VLDL, and HDL (46).  It has demonstrated that there is a 
positive correlation between plasma levels of Apo C-III and VLDL-TG concentrations (1).   
Although the mechanism is unclear, Apo C-III is known to inhibit TRL clearance.  Overexpression 
of Apo C-III links to pronounced HTG in transgenetic mouse through the inhibition of TRL 
clearance (47).  Also, a deficiency in Apo C-III in humans appears to increase the rate of TG 
clearance from plasma (48).   A drug beta,beta'-tetramethylhexadecanedioic acid (MEDICA 16) is 
capable of reducing TG levels by the suppression of Apo C-III gene expression in rodents (49, 
50).    
 The mechanism by which Apo C-III reduces TG clearance is unclear.  It has been 
proposed that Apo C-III has a negative charge on the surface of LP, and this may inhibit other 
nonspecific interactions with cell surfaces and maybe other LP.  Apo C-III may also interfere with 
lipolysis because it reduces the affinity of TRL to lipases, such as LPL, or certain surface 
receptors such as those binding to Apo E or Apo B (45, 49).     
 On the other hand, Apo E plays a role in the removal of plasma LP.  The first phase of 
TG clearance in peripheral tissues relies on the endothelial bound LPL.  LPL prefers to break 
down TG in CM and VLDL remnants.  Almost all CM remnants and VLDL remnants are taken up 
by the liver and broken down.  Apo E may also play a role in the action of LPL and HL.  These 
enzymes play an important role in converting VLDL remnants into LDL (49).  Remnants will 
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accumulate and may result in dysbetalipoproteinemia if there is a lack of Apo E. 
Dysbetalipoproteinemia is a highly atherogenic mixed hyperlipidemia, which is associated with the 
accumulation of remnants of TRLs.  Apo E plays a role in the binding of these remnants to 
hepatic lipoprotein receptors (51).   
Treatment of Diabetic Dyslipidemia  
 The therapeutic plan for T2DM begins with modifications of lifestyle, such as physical 
activity, changes in diet, weight loss, and smoking cessation (7).  Epidemiologic and intervention 
studies have also shown that medical nutrition therapy and physical activity can significantly 
improve the measurements of diabetic dyslipidemia.  Currently, there are recommendations for 
the management of dyslipidemia in patients with T2DM.  For example, evidence shows that a low 
carbohydrate diet is beneficial in achieving weight loss and improving lipid and LP levels.   Even 
though these behavioral interventions are important for the improvement in diabetic dysipidemia, 
this is often concomitant with pharmacological therapy.  Statins, fibrates, niacin, and TZD are 
commonly used to treat dyslipidemia associated with insulin resistance and T2DM (7).   
Statins (HMG-CoA Reductase Inhibitors) 
 The primary roles of statins on LP metabolism are controlled by increased LDL receptor 
activity (7).  However reduced hepatic LP secretion also seems to serve an important part.  While 
statins can lower plasma levels of all LDL subclasses and IDL, they can also reduce plasma TG 
levels and raise HDL cholesterol.   
Fibrates (PPAR-α Agonists)  
 The primary action of fibrates is the reduction of TRL (7).  Transcriptional regulation of 
genes, such as LPL and its activator Apo C-II and inhibitor of Apo C-III, plays an important role in 
this action.  Fibrates also increase HDL via the increased production of HDL apoproteins and 
reduced transfer of cholesteryl ester from HDL to VLDL.  Even though the effects of fibrates on 
LDL cholesterol are inconsistent, reductions are usually small (7).  Fenofibrate treatment has 
been shown to be effective in normalizing the atherogenic dyslipidemic phenotype in patients with 
T2DM (7).   
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 The use of statins and fenofibrate taken together have been shown to be highly beneficial 
in patients with T2DM and combined hyperlipidemia, who exhibit increased LDL cholesterol, low 
HDL cholesterol, and elevated TG levels.  After 24 weeks of both statins and fenofibrate 
treatment, LDL cholesterol was reduced by 46%, TGs were reduced by 50%, and HDL 
cholesterol was increased by 22% (5).  Small dense LDLs were also reduced by the combined 
therapy.  One limitation concerning this combination therapy is increased toxicity.  Recent studies 
have suggested that the risk seems to be much greater with gemfibrozil than with fenofibrate (7).   
Niacin 
 Niacin has been proven to significantly lower TG levels, increase HDL levels, and 
increase LDL particle size (7).  The mechanism by which niacin helps improve the LP profile is 
that this water-soluble vitamin reduces fatty acid release from adipose tissue and suppresses 
hepatic production of VLDL.  As a result, TG levels will decrease as well as the number of small 
dense LDL particles.  Studies have shown that niacin also raises HDL levels by reducing uptake 
via the receptor responsible for intrahepatic degradation of HDL.  However, while niacin may 
provide useful information in the development of new treatments for diabetic lipidemia, it is not 
recommended because studies have shown that high doses of niacin may worsen glycemic 
control.  A 16-week double blind placebo-controlled study was performed to determine if there 
was a difference between the placebo and niacin treatment.  This study included 148 patients 
with T2DM and dyslipidemia.  The patients were randomly divided to placebo treatment or 1,000 
or 1500 mg/day of extended-release niacin.  Also, about half the patients received statin therapy 
along with placebo or niacin treatment.  Niacin in amounts of 1000 or 1500 mg/day increased 
HDL cholesterol by 19 and 24% respectively in relation to the placebo group.  The niacin 
treatment also reduced TG levels by 13 and 28%.  Glycemic control in patients changed very little 
with the 1000 mg dose, except in 4 patients who had to stop participating in the study because of 
inadequate glycemic control (7). 
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Thiazolidinediones (TZDs) (PPAR-γ Agonists) 
 Thiazolidinediones (TZDs) are PPAR-γ agonists that have insulin-sensitizing effects, 
which can improve glucose control in patients with T2DM.  TZDs are not the recommended 
treatment for dyslipidemia.  However, some evidence demonstrates that TZDs may have 
favorable effects on LP profile and may also be seen as an important improvement for the certain 
trends of dyslipidemia in diabetic patients.  Patients with diabetes often see comparable effects 
on lipid profiles if given one of PPAR-γ treatments, such as TZDs, rosiglitazone and pioglitzone.  
TZD treatment often tends to increase total and LDL cholesterol but there is also a constant rise 
in HDL cholesterol.  Pioglitazone therapy often lowers TG levels; TG levels also decrease with 
rosiglitazone in patients who have elevated baseline TG levels.  An observational cohort study 
was performed to assess TZD therapy.  Results indicated that TZD treatment significantly 
increased LDL particle size and increased the larger HDL2 subfraction by 24%.  Further, 
rosiglitazone therapy for 8 weeks significantly increased HDL cholesterol levels by 6% and HDL2 
by 12.6% (7).  Combination of atorvastatin and rosiglitazone treatment resulted in a 5% increase 
in HDL was observed.  A significant decrease in LDL (-39%) and TG (-27%) was also seen.  
Pioglitazone has also been known to have a positive impact on atherogenic dyslipidemia in 
patients with T2DM.  In one study comprising of 54 nondiabetic patients with arterial hypertension, 
small dense LDL levels were elevated in 63% of subjects at baseline.  However, after 16 weeks, 
pioglitazone treatment seemed to reduce dense LDL particles by 22% (7).   
TZDs action also decreases the expression of tumor necrosis factor (TNF-α) in 
adipocytes, cytokines produced from adipose tissue.  The functions of TNF-α include impairing 
insulin receptor signaling, inhibiting LPL, and stimulating lipolysis in fat cells (24).  This should 
lead to an increased availability of FA for muscles and may result in insulin resistance.  In animal 
models of obesity, the gene expression of TNF-α is over-expressed in adipose tissue.  
Furthermore, interleukin (IL)-6 secreted from adipocytes is negatively correlated to insulin action.  
The action of TZDs on IL-6 is poorly understood.  However, TZDs can decrease IL-6 production 
by monocytes (24).   
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V.   MODELS FOR DIABETIC DYSLIPIDEMIA  
 Laboratory animal models exhibit comparable disease states with humans.  For this 
reason, they serve as a powerful aid in human studies.  These models overcome difficulties in 
human studies, such as uncontrolled diets or lifestyle.  Animal models share both physiological 
and genetic similarity with humans.  Therefore, the information identified in animal models can be 
applied to humans (12).   
Tsumura, Suzuki, Obese Diabetes (TSOD) Mouse  
Tsumura, Suzuki, Obese Diabetes (TSOD) male mice are characterized by polydipisia 
and polyuria at 2 months old (52).  Hyperinsulinemia and hyperglycemia usually follow.  After 
these symptoms, obesity will develop until about 12 months.  Severe hypertrophy of pancreatic 
islets due to proliferation and swelling of beta cells has also been observed in TSOD mice.  At 18 
months old, the kidney showed thickening of the basement membrane in glomeruli and an 
increase of the mesangial area.  TSOD mice began to experience motor neuropathy at 14 months 
of age, and most male mice at 17 months of age began to feel weakness in their front and hind 
paws due to neuron degeneration in the peripheral nerve.  The mice at 12 months of age showed 
a significantly reduced of tail pressure.  Using light microscopic and electron microscopic 
technology, it has been found that the sciatic nerves had a decrease in the density by endoneural 
fibrosis and loss of these fibers in TSOD mice.  Also, there were degenerative changes seen in 
myelinated fibers, separation of myelin sheaths, and remyelination.  Furthermore, the lamellar 
structure was completely destroyed and microphages were present around myelin sheath (52).  
Otsuka Long-Evans Tokushima Fatty (OLETF) Rats  
Another spontaneous animal model for T2DM includes the Otsuka Long-Evans 
Tokushima Fatty (OLETF) rats.  OLETF rats show a late onset of chronic and slowly progressive 
hyperglycemia and polyphagia, which leads to body weight gain, resulting in hyperinsulinemia, 
HTG, and hyperglycemia (29).  Past the age of 40 wks, the rats become hypoinsulinemic, and 
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they also have defects in insulin secretion.  Histologically, the OLETF rats exhibit the progressive 
fibrosis in the pancreas (29).  
Nagoya-Shibata-Yasuda (NSY) Mice 
The Nagoya-Shibata-Yasuda (NSY) mice are an inbred model of T2DM, established from the 
same colony as JcI:ICR.  Shibata (19) began selective breeding for glucose tolerance, and shortly 
thereafter, this NSY strain of mice showed impaired glucose tolerance.  The development of 
diabetes in NSY mice is age dependent, both impaired insulin secretion and action play a role in  


































CHAPTER 3: EXPERIMENTAL INVESTIGATIONS  
 
ABSTRACT 
The TALLYHO/Jng (TH) mouse strain is a polygenic inbred model for type 2 diabetes 
mellitus (T2DM) and obesity.  TH mice are characterized by insulin resistance, hyperinsulinemia, 
hyperglycemia (males), obesity, and hypertriglyceridemia (HTG) in combination with increased 
plasma free fatty acid concentration as well as increased total and high density lipoprotein (HDL) 
cholesterol levels.  Previous work in this laboratory demonstrated that HTG precedes the overt 
diabetes and is profoundly associated with insulin resistance and hyperglycemia in male TH mice.  
The aim of the present study is therefore to characterize the pathophysiology of HTG in TH mice 
and test the hypothesis that lowering the plasma triglyceride (TG) levels will improve insulin 
resistance and glucose metabolism in this model.  HTG could result from either a defect of 
plasma TG catabolism or hepatic over-production of TG.  To examine these questions we 
determined hepatic TG secretion by the Triton WR-1339 methodology (inhibition of peripheral 
lipolysis) and exogenous TG clearance (after i.v. injection of radiolabeled very low density 
lipoprotein-TG (VLDL-TG)).  There was no significant increase in TG production in TH mice; 
however the clearance of VLDL-TG was significantly decreased in these mice compared to 
C57BL/6J (B6) controls.  Moreover, Apolipoprotein C-III (Apo C-III), a key component in the 
metabolism of plasma TG, gene expression was upregulated in TH mice, while there was no 
difference in gene expression of lipoprotein lipase, a key enzyme for TG hydrolysis, in TH and B6 
mice.  A lipid lowering agent, bezafibrate (BF), treatment, significantly reduced plasma TG levels 
and reduced plasma insulin levels in TH mice.  BF, however, did not change glucose tolerance 
and uptake or glycemia in TH mice.  In summary, these results suggest that the HTG in TH mice 
is caused by reduced VLDL-TG clearance, possibly mediated through increased Apo C-III.  Also, 
the early development of HTG does not appear be directly responsible for diabetes in TH mice. 
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I.  INTRODUCTION 
 Diabetes and its health related problems are on the rise in the United States.  While 20.8 
million Americans have diabetes, 6.2 million cases go undiagnosed, and approximately 800,000 
new cases of diabetes are detected every year, or 2,200 per day (14, 15).  Further, 97% of adults 
with diabetes have one or more lipid abnormalities, such as decreased high density lipoprotein 
(HDL) cholesterol, a predominance of small dense low density lipoprotein (LDL) particles and 
increased triglyceride (TG) levels (7, 24).  Type 2 diabetic patients usually have LDL cholesterol 
levels that are often the same to those in nondiabetic patients (53).  Hypertriglyceridemia (HTG), 
on the other hand, is a major feature of the dyslipidemia found in type 2 diabetes mellitus (T2DM) 
and typically implies increased levels of very low density lipoprotein (VLDL)-TG (54).    
 Genetic animal models have been valuable resources for T2DM research, and few 
polygenic rodent models, where multiple genes are involved in the development of the disease, 
have been developed (9).  These models include the Goto-Kakizaki (GK), Otsuka Long-Evans 
Tokushima Fatty (OLETF) rats, Spontaneously Diabetic Torii (SDT) rats, the Nagoya-Shibata-
Yasuda (NSY) mice, the Tsumura-Suzuki-Obese-Diabetes (TSOD) mice (10) and the NZO/NON 
F1 hybrid mice (11).   
  The TALLYHO/Jng (TH) mice are a newly established polygenic model for T2DM 
characterized by obesity, hyperinsulinemia, insulin resistance, hyperglycemia (males), and 
dyslipidemia associated with increased TG, free fatty acid, and cholesterol levels (12).  Our 
longitudinal study has revealed that TH male mice exhibit a striking rise in plasma TG levels 
between 6 and 10 wks of ages where their plasma glucose levels are in the phase of steady 
rising.  On the other hand, normoglycemic TH female mice do not exhibit this TG spike although 
they maintained HTG compared to B6 control mice (12).   
The aim of the present study was to characterize the pathophysiology of HTG in TH mice 
and test the hypothesis that lowering the plasma TG levels will improve insulin resistance and 
glucose metabolism in this model.     
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II.  MATERIALS AND METHODS 
Animals 
 Mice were maintained on standard rodent chow with 4% fat [5K54, PMI Feeds, Inc., St. 
Louis, MO or Harlan Teklad Rodent Diet (W) 8604, WI] ad libitum with free access to water (HCl 
acidified, pH 2.8-3.2) under controlled temperature and humidity with a 12-hour light and dark 
cycle.  Since the diabetic trait is polygenic in TH mice a simple genetic control of non-diabetic 
mice does not exist.  Therefore, C57BL/6J (B6) inbred mice were used as arbitrary control since 
B6 is one of the most commonly used strains in diabetes and obesity research and does not 
develop diabetes when fed standard laboratory chow (12).   
All animal studies were carried out with the approval of The University of Tennessee Animal 
Care and Use Committee.  Mice were euthanized by CO2 asphyxiation. 
In Vivo Hepatic TG Production 
 Hepatic production of VLDL-TG was measured after intraperitoneal injection of Tyloxapol 
(Triton WR 1339) (T0307-50G, Sigma, St. Louis, MO) (0.5mg/1g body weight) in saline on mice 
fasted overnight.  Blood was collected from the retro-orbital plexus using heparinized 
microcapillary tubes (22-362-566, Fisher Scientific; Pittsburgh, PA), at 0, 1, 2, 3, and 4 hr time 
points after injection, and plasma was obtained by centrifugation (1,200g) at 4ºC.  Plasma levels 
of free and total glycerol were determined using commercial colorimetric assay (TR0100, Sigma, 
St. Louis, MO) and plasma triglyceride concentrations were estimated by subtraction of free 
glycerol from total glycerol levels. 
In Vivo TG Clearance   
 TG clearance was examined by the clearance of radiolabeled TG from a single 
preparation of in vivo-labeled VLDL from B6 mice, prepared as described  (55).  Briefly, [3H] 
palmitic acid (P-1076, Sigma) was redissolved in saline containing 4mg/ml bovine serum albumin 
(690-A, Sigma) to a final concentration of 1mCi/ml.  Twenty C57BL/6J (B6) mice were fasted 
overnight and injected intravenously through the tail vain with a bolus of [3H] palmitic acid (100 µl 
per mouse).  Mice were then killed 25 minutes after injection, and blood was collected via cardiac 
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puncture.  Plasma was obtained by centrifugation (1,200g) at 4°C.  Radiolabeled VLDL for use in 
the clearance study was isolated using a solution of 15.3% NaCl and 35.4% KBr (final 
concentration 0.65% and 1.52%, respectively) in 0.9% NaCl with a density < 1.019.  Plasma (2.4 
ml) was added on top of the NaCl-KBr solution (9.6 ml) and ultracentrifuged 16 hours at 40,000 x 
g at 4ºC (56).  The tube was sliced using tube slicer (303811, Beckman) (57), and VLDL was 
withdrawn at 1.5 cm from the top portion using a pipette.  Overnight fasted TH and B6 male mice 
were injected intravenously through the tail vain with 63,418 dpm of radiolabeled VLDL-TG.  
Blood was collected from the retro-orbital plexus using heparinized microcapillary tubes, at 5, 10, 
15, and 20 minute (min) time points after injection.  Plasma was obtained by centrifugation 
(1,200g) at 4°C.  Ten µl of plasma was dissolved in 4 ml of SOLVABLE (6NE9100 Perkin Elmer, 
Wellesley, MA) and the radioactivity was counted in a scintillation counter (LS3801, Beckman, 
Fullerton, CA).  The rate of clearance of VLDL-TG was determined by the disappearance of tracer, 
assuming the value obtained at 0 min to be 100% of the injected dose (55).   
Northern Blot Analysis 
 Total RNA was extracted from the liver tissue of B6 and TH male mice using a RNeasy 
Midi Kit (75142, Quiagen, Valencia, CA).  The RNA was size fractionated on a 1% agarose/2.2M 
formaldehyde gel, transferred by capillary action to Hybond N+ (RPN303B, Amersham, 
Piscataway, NJ), and hybridized with random primed (RPN1633, Amersham) α-32P-labeled 
apolipoprotein C-III (Apo C-III) cDNA probe.  The probe was obtained by reverse transcription-
polymerase chain reaction (RT-PCR) using the primers (forward: 5′-
AACAAGCCTCCAAGACGGTC-3′, reverse: 5′-GGTCCTCAGGGTTAGAATCC-3′) derived from 
the mouse Apo C-III cDNA.  The blots were washed in 2 X SSC/0.1% SDS and in 0.5 X 
SSC/0.1% SDS at 65ºC for 20 min each and then exposed to X-ray film at –80ºC.  Quantification 
is conducted using ImageJ processing (JAVA).   
Real Time RT-PCR 
 Quantitation of relative gene expressions of lipoprotein lipase (LPL) was performed by 
the real-time quantitative PCR using the ABI PRISM 7300 Sequence Detection System (4345250, 
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Applied Biosystems, Foster City, CA).  Total RNA was extracted from the adipose tissue of B6 
and TH male mice using RNeasy Lipid Tissue Midi Kit (75842, Quiagen, Valencia, CA) following 
the manufacture’s protocol.  The RNA (2 µg) was then reverse-transcribed in a total volume of 20 
µl with SUPERSCRIPT RT (Gibco BRL, Carlsbad, CA) using oligo d(T)12-18 as a primer following 
the manufacturer’s instructions.  Reference cDNA was synthesized using pooled RNA (total 2 µg) 
collected from all the samples including B6 (n=3) and TH (n=3).  The primers used for the real-
time PCR were proprietary for mouse LPL and mouse 18S (PPM04353A-200 and PPM57735A-
200, respectively, SuperArray, Frederick, MD).  Amplification of mouse 18S was performed to 
standardize the quantification of target cDNA.  Briefly, 0.2, 0.04, 0.008, and 0.0016 µl of the 
reference cDNA were amplified for LPL and 18S to create a standard curve.  Likewise, 0.04 µl of 
cDNA were amplified in all isolated mouse adipose tissue samples.  PCR reactions were 
performed in a 25-µl volume with 0.4 µM primers and RT² Real-Time™ SYBR Green/ROX PCR 
master mix (PA-012, SuperArray, Frederick, MD).  Amplification was achieved by denaturation 
(melting) at 95ºC for 30 sec, followed by 55ºC for 30 sec (annealing), and elongation at 72ºC for 
35 sec.  These steps were repeated for 39 cycles.  After 39 cycles, amplification continued at 
72ºC for 5 min.  A dissociation step was added at 95ºC for 15 sec and at 60ºC for 30 sec to make 
sure that nothing other than the gene of interest was amplified during the reaction.  After the 
standard curves were calculated, the input amounts of cDNA of the unknown samples were 
calculated for LPL and 18S. After the input amount of the probe sample was normalized to the 
18S expression, the relative amount of the expressed RNA species in each unknown sample was 
calculated.   
Bezafibrate Treatment  
 Diets and body and fat pad weights: At 6 weeks of age, mice were fed customized 
bezafibrate (B7273, Sigma) (1.5 g/kg of diet) containing or regular chow diet for 15 weeks.  Body 
weights were measured weekly.   At the end of the study, mice were killed, and five white 
(including inguinal, epididymal, mesenteric, retroperitoneal (including perirenal), and subscapular) 
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and brown fat pads were dissected and weighed to measure adiposity.  Carcass weights (body 
weight without the white fat pads) were then measured.   
 Plasma Glucose, Insulin, and TG levels: Blood was drawn between 7:30 and 10:30 AM 
from the retro-orbital plexus using heparinized microcapillary tubes, and plasma was obtained by 
centrifugation (1,200g) at 4°C.   Plasma TG (TR0100, Sigma) and glucose (TR15221, Thermo 
Electron, Louisville, CO) levels were determined using commercial colorimetric kits.  Plasma 
insulin levels were determined using RIA kits (RI-13K, Linco Research, St. Charles, MO). 
Intraperitoneal Glucose Tolerance Test: Mice were fasted overnight and then injected 
intraperitoneally with glucose (1mg/g body weight) in saline.  Blood was drawn from the retro-
orbital plexus using heparinized microcapillary tubes at 0, 30, 60, and 120 min after injection.  
Plasma was obtained by centrifugation (1,200g) at 4°C.  Plasma glucose levels were then 
determined using a commercial colorimetric kit as described above.    
Tissue Glucose Uptake: Overnight fasted mice were injected intravenously through the 
tail vein with a bolus of 2-Deoxy-D-Glucose 1,2-3 H(N) (2-DG) (D4539, Sigma) (10µCi)/mouse (58) 
in saline either with or without insulin (I-5523, Sigma) (1U/ml).  The mice were euthanized by CO2 
asphyxiation 30 min after injection.  Epididymal fat pads and soleus muscle were then collected, 
washed, blot dried, and weighed, and dissolved in 1M-NaOH solution at 60°C (fat pads) or in 
SOLVABLE (soleus muscle) (6NE9100, Perkin Elmer).  The incorporated radioactivity was 
counted in a scintillation counter (LS3801, Beckman).  The 2-DG uptake was expressed as the 
counts per minute divided by tissue weight (58).     
Statistical Analysis 
Data analysis was conducted by ANOVA with StatView 5.0 (Abacus Concepts, Berkeley, 




Hepatic VLDL-TG Production  
To evaluate hepatic VLDL production, overnight fasted B6 and TH mice were injected 
with Triton WR 1339 to block LPL-mediated TG hydrolysis, and the accumulation of TG (VLDL-TG) 
in plasma was monitored over time.  As shown in figure 1, basal TG levels were significantly 
different between TH and B6 mice, but maximum secretion was not.    
VLDL-TG Clearance 
To determine whether HTG in TH mice is associated with TG removal, we examined the 
plasma clearance of [3H] TG-labeled VLDL obtained from B6 control mice.  The mean percentages 
of residual [3H] TG-labeled VLDL in the plasma are depicted in figure 2.  TH mice showed a 
significantly increased residual percentage of injected [3H] TG-labeled VLDL at all sampling times 
compared to B6 mice, indicating slower clearance rate in TH mice than in B6 mice. 
Gene Expression Levels of Apo C-III and LPL 
Consistent with studies demonstrating that over-expression of Apo C-III is positively 
associated with pronounced HTG (59, 60), the gene expression level of Apo C-III  was higher in 
TH mice compared to B6 mice as shown in the autoradiographs (figure 3).  There was no 
difference in gene expression of LPL between TH and B6 mice (figure 4).  
Effects of Bezafibrate Treatment 
 Body and fat pad weights: Fat pads and carcass weights were significantly higher in TH 
mice compared to B6 mice on chow (figures 5 & 6).  BF treatment did not change adiposity in 
these mice (figures 5 & 6).   
Plasma Levels of TG, Glucose, and Insulin: At 6 week of age, the basal plasma TG levels were 
significantly higher in TH mice compared to B6 mice (figure 7).  BF treatment markedly lowered 
plasma TG levels both in TH and B6 mice (figure 7).  Plasma glucose levels of both TH and B6 
mice were similar throughout the study showing no significant effect of BF (figure 8).  The basal 
plasma insulin levels in TH mice were significantly higher than those in B6 mice at 6 weeks of age, 









0 1 2 3 4






Figure 1.  Hepatic VLDL TG production in B6 and TH mice.  Triton WR 1339 (0.5mg/1g body 
weight) was injected into fasted B6 (open squares) and TH (filled squares) at 8 wks of age.  
Plasma TG levels were determined at the indicated time points and corrected for the TG level 
at the time of Triton injection (0 min).  The values represent means ±  SEM of 5 mice/group.  *p 
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Figure 2.  Clearance of VLDL (d < 1.019) in B6 and TH mice.  VLDL labeled on its TG moiety 
was obtained 25 min after injecting B6 mice with [3H] palmitate.  The isolated labeled VLDL 
was then injected (63,418 dpm/ mouse) into B6 and TH mice at 12 weeks of age.  At the 
indicated times, blood (<50 µl) were taken, and radioactivity in plasma of 10 µl was counted.  
The plasma decay of the label was more rapid in B6 (open squares) than in TH (closed 
squares) mice.  The values represent means ± SEM of 9 mice per group.  *p<0.05 vs. B6 at the 



























Figure 3.  Autoradiograph of Northern blot analysis for Apo C-III gene in the liver from B6 (n=4) 
and TH (n=4) mice (males, 12 weeks).  Total RNA was loaded for each sample.  Northern blot 
hybridization was carried out with a mouse Apo C-III cDNA probe and equal loading was verified 
by hybridization to an 18S rRNA probe. 
 
    
      

























































Figure 4.  Lipoprotein lipase mRNA levels by real-time RT-PCR analysis in B6 (n=3) and TH 
(n=3) mice (males, 12 weeks). Values are displayed as relative abundance after 

















































Figure 5.  Fat pad weights in TH and B6 mice fed chow and bezafibrate-treated (BF) diets for 15 
wk beginning at 6 wk of age (males).  At the end of the study, mice were euthanized, five white 
fat pads [inguinal, epididymal, mesenteric, retroperitoneal (including perirenal), and subscapular] 
were dissected and weighed.  The first two bars in the group represent TH mice and the last two 
bars represent B6.  Vertical lines represent chow and horizontal lines BF diets, respectively 
(males, n = 3-11 for each group).  Values are expressed as means ± SEM.  *p<0.05 vs. B6 
mice.  There was no significant diet effect.  



















Figure 6.  Carcass weights (body weight without the five white fat pads) in TH and B6 mice fed 
chow and bezafibrate-treated (BF) diets for 15 wk beginning at 6 wk of age (males).  The first 
two bars in the group represent TH mice and the last two bars represent B6.  Vertical lines 
represent chow diet and horizontal lines BF diets, respectively.  *p <0.05 vs. B6 mice. There was 

































































Figure 7.  Changes in plasma triglyceride levels in TH (a) and B6 (b) mice fed chow and 
bezafibrate-treated (BF) diets for 15 wk beginning at 6 wk of age (males).  Blood was drawn 
between 7:30 and 10:30 AM from the retroorbital plexus using heparinized microcapillary 
tubes, and plasma was obtained by centrifugation (1,200 g) at 4°C.  Plasma TG levels were 
then determined using a commercial colormetric kit. Open and filled symbols represent BF 
and chow diets, respectively (non-fasting, n = 6-15 for each group).  Values are expressed as 
























Figure 8.  Changes in plasma glucose levels in TH and B6 mice fed chow and bezafibrate-
treated (BF) diets for 15 wk beginning at 6 wk of age (males).  Blood was drawn between 7:30 
and 10:30 AM from the retroorbital plexus using heparinized microcapillary tubes, and plasma 
was obtained by centrifugation (1,200 g) at 4°C.  Plasma glucose levels were then determined 
using a commercial colormetric kit. Squares and triangles represent TH and B6, respectively.  
Open and filled symbols represent BF and chow diets, respectively (non-fasting, n = 6-15 for 










































Figure 9.  Changes in plasma insulin levels in TH and B6 mice fed chow and bezafibrate-
treated (BF) diets for 15 wk beginning at 6 wk of age (males).  Blood was drawn between 7:30 
and 10:30 AM from the retroorbital plexus using heparinized microcapillary tubes, and plasma 
was obtained by centrifugation (1,200 g) at 4°C.  Plasma insulin levels were then determined 
using a RIA kit. Squares and triangles represent TH and B6, respectively.  Open and filled 
symbols represent BF and chow diets, respectively (male, non-fasting, n = 3-12 for each 












BF treatment slightly, but significantly, decreased plasma insulin levels in TH mice at 16 weeks of 
age, 10 weeks on the treatment (figure 9).   
Intraperitoneal Glucose Tolerance Test: TH mice exhibited impaired glucose tolerance compared 
to B6 mice (figure 10).  BF treatment did not improve glucose tolerance in TH mice (figure 10).   
Glucose uptake: The effect of BF treatment on glucose uptake, the first step of glucose 
metabolism in the body, was tested in vivo in the insulin sensitive soleus muscle and epididymal 
fat of TH mice, using 2-DG (a glucose analogue that is taken up by cells but not metabolized).  
BF treatment did not improve 2-DG uptake in either soleus muscle or epididymal fat pad in TH 
mice (figure 11 and 12).   
IV.  DISCUSSION 
 HTG, the most commonly seen lipid abnormality in T2DM, can result from an increased 
hepatic production of VLDL-TG that leads to increased VLDL-TG secretion, or a delayed 
catabolism of plasma TG, or both (61).  In this study, we have found a marked reduction in VLDL-
TG clearance rate in TH mice compared to B6 mice without a significant difference in hepatic 
VLDL-TG production (figures 1 and 2).  There was also evidence that the Apo C-III gene 
expression was upregulated in the liver of TH mice (figure 3).  Further, our study demonstrated 
that lowering plasma TG with BF treatment failed to improve glucose metabolism in TH mice 
(figures 5-12). 
Like in TH mice, the HTG in streptozocin-induced diabetic rats is due to reduced VLDL-
TG catabolism while the secretion rate of TG is normal (62, 63).  This demonstrates that HTG is 
attributable to a defect of TG clearance either in insulin resistance or deficiency.   
The molecular mechanism of HTG, however, remains unclear.  Various research groups 
have investigated the roles of apolipoproteins in the regulation of TG metabolism through in vitro 
and in vivo studies.  An increasing body of evidence has implicated Apo C-III as a contributing 






















Figure 10.  Glucose tolerance test in TH and B6 mice fed chow and bezafibrate-treated (BF) 
diets for 15 wk beginning at 6 wk of age (males, 17 wks of age).  Mice were fasted overnight 
and injected intraperitoneally with glucose (1mg/g body weight) in saline. Blood was collected 
via the retroorbital plexus using a heparinized microcapillary tube at 0, 30, 60, and 120 min after 
injection.  Plasma glucose levels were then determined using a commercial colorimetric kit. 
Squares and triangles represent TH and B6, respectively. Open and filled symbols represent 
BF and chow diets, respectively (n = 5-7 for each group).  Values are expressed as means ± 












































Figure 11.  In vivo 2-deoxy-D-glucose 1, 2-[3H] (N) (2-DG) uptake in soleus muscle in TH mice 
fed chow and bezafibrate-treated (BF) diets for 15 wk beginning at 6 wk of age (males, 18 wk, n 
= 2- 4 for each group). Mice were fasted overnight and injected with a bolus of 2-DG in saline 
without (W/O) or with insulin and tissue was harvested 30 min after the injection.  
































































Figure 12.  In vivo 2-deoxy-D-glucose 1, 2-[3H] (N) (2-DG) uptake in epididymal fat in TH mice 
fed chow and bezafibrate-treated (BF) diets for 15 wk beginning at 6 wk of age (males, 18 wk, n 
= 4 for each group).  Mice were fasted overnight and injected with a bolus of 2-DG in saline 
without (W/O) or with insulin and tissue was harvested 30 min after the injection. Epididymal fat 
pads were collected, washed, blot dried, weighed, and dissolved in 1 M NaOH at 60°C. 
Incorporated radioactivity was counted in a scintillation counter.  2-DG uptake is expressed as 



































Apo C-III, mainly synthesized in the liver, is a 79 amino acid protein with a molecular 
mass of 8.8 kDa and becomes a component of chylomicrons (CM), VLDL and HDL  (64).  It has 
been demonstrated that elevated Apo C-III levels are positively associated with HTG in humans 
(65, 66).  In addition, over-expression of the human and mouse Apo C-III gene in transgenic mice 
results in HTG, the severity of which is associated with the levels of plasma Apo C-III (46, 67).  
Apo CIII deficient mice, on the other hand, develop hypotriglyceridemia (47).  
The causal link between overexpression of Apo C-III and HTG has been demonstrated by 
impaired clearance of VLDL-TG.  Apo C-III transgenic mice had impaired clearance of VLDL-TG 
(67), whereas Apo C-III null mice exhibited an increased catabolic rate of VLDL-TG (44).  The 
hypotriglyceridemia shown in Apo C-III null mice is primarily due to an increased hydrolysis of 
VLDL-TG via LPL (44), (68).  LPL, a 52-kD protein, is a rate-limiting enzyme for TG hydrolysis in 
CM and VLDL (69-71).  It has been known that Apo C-III inhibits LPL function, although the 
mechanism is unknown.  On the basis of in vitro studies, the proposed mechanism by which Apo 
C-III inhibits LPL activity includes either a direct interaction of Apo C-III with LPL (70), or a 
hampered binding of the Apo C-III-enriched lipoprotein particles to heparan sulfate proteoglycan-
LPL matrix on the surface of endothelial cells (72).  However, in vivo evidence has demonstrated 
that Apo C-III inhibits the interaction of VLDL with heparan sulfate proteoglycan rather than acting 
as a direct inhibitor of LPL (67, 68, 73).  In the present study, we did not test clearance of VLDL 
particles from TH mice.  Therefore, it remains unknown whether the slowed clearance of VLDL 
from TH mice is attributable to an altered composition of VLDL particles, or to a problem in VLDL-
TG hydrolysis system, because it is possible that a rapid exchange of apolipoproteins occurs 
between injected VLDL derived from the control B6 mice and the recipient TH lipoproteins during 
the VLDL clearance test.  Although there was no evidence of downregulation of LPL mRNA in TH 
mice, LPL activity study is required to address this question.  Also, the clearance test using VLDL 
derived from TH mice is required to be conducted to understand the effect of VLDL component on 
the hydrolysis of TG.   
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It is well known that diabetes is associated with a reduction of LPL activity at the 
posttranscriptional level (38, 73, 74).  Therefore, it is possible that LPL activity may be reduced in 
TH mice due to insulin resistance, and overproduction of Apo C-III causes further functional 
deficiency of LPL in TH mice.    
Several studies have implicated that dyslipidemia can be responsible for altered insulin 
action and glucose metabolism.  Roden et al (1996) demonstrated that an intravenous infusion of 
a TG emulsion into healthy individuals decreased muscle glycogen synthesis and the rate of 
whole-body glucose uptake (75).  Dresner et al. (1999) also demonstrated that lipid infusion 
abolished insulin signaling (34).  Normalization of TG levels lowered fasting plasma glucose 
levels more than 3 times and improved insulin sensitivity in subjects with extreme HTG and overt 
diabetes (76).  Previously, we have found that insulin resistance is profoundly associated with 
HTG in male TH mice (unpublished data).  However, it is unknown whether the HTG is the 
primary defect for the reduced insulin sensitivity or the secondary to the insulin resistance in TH 
mice.  Therefore, in the present study we examined the effect of a lipid lowering drug bezafibrate 
on insulin sensitivity in TH mice.   Bezafibrate is known to selectively decrease plasma TG levels 
without affecting blood glucose levels (77).   
Bezafibrate treatment significantly lowered the plasma TG levels both in TH and B6 mice 
until the end of the study period.  Despite lowering plasma TG levels, bezafibrate treatment did 
not improve glucose tolerance and uptake in TH mice, although it slightly ameliorated 
hyperinsulinemia at the late stage of the study.  Glucose tolerance and insulin stimulated 2-DG 
uptake in epididymal fat even worsened with bezafibare treatment in TH mice.  Presently, we 
have no explanation for these changes.  Collectively, these findings suggest that the HTG may 
not be responsible for the altered glucose metabolism in TH mice.   
A lack of bezafibrate effect on improving glucose metabolism was also shown in Zucker 
Diabetic Fatty (ZDF) rats (77).  Also, Jia et al (29) only found a minor effect of bezafibrate on 
insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty (OLETF) rats.  In contrast, BF 
treatment significantly decreased fasting serum insulin, glucose and TG levels and improved 
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insulin sensitivity in non-obese Japanese type 2 diabetic subjects (31).  Also, Matsui et al have 
reported that bezafibrate treatment improves insulin sensitivity in Sprague-Dawley rats fed high-
fructose and lard diets (78).  These contradictory effects of bezafibrate on insulin sensitivity and 
glucose metabolism might be associated with differences in species, doses and durations used in 
different studies.   
In summary, the HTG appears to be due to a defect in TRL-TG clearance in TH mice, 
and overproduction of Apo C-III may be in part involved in the pathogenesis.  The HTG is not 
likely responsible for the impaired insulin action in TH mice, but insulin resistance may be the 
primary defect.  These results shed light on the mechanism underlying the HTG in obese type 2 
diabetic TH mice, which may contribute to understanding the pathophysiology of diabetic HTG in 





























CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 
 
It has long been recognized that diabetes is a disorder not only of carbohydrate 
metabolism, but also of lipid metabolism.  HTG is the dominant dyslipidemia observed in diabetic 
patients, especially with T2DM, and is known to be a strong risk factor for coronary heart disease 
(CHD) in T2DM.  However, the molecular mechanism underlying the diabetic HTG is largely 
unknown.  In the present study, we have found that obese type 2 diabetic TH mice have defective 
VLDL-TG clearance.  In support of the slowed VLDL-TG clearance rate, we also found evidence 
of hepatic over-expression of the Apo C-III gene, known as an inhibitor of LPL, in TH mice.  The 
activity of LPL in TH mice requires to be determined.  In addition to Apo C-III, other 
apolipoproteins including Apo C-II and Apo A-V are known to be important regulators for plasma 
TG metabolism.  Apo C-II and Apo A-V are both specifically expressed in the liver and augments 
lipolysis of plasma TG (79) (40).  Studying abnormalities in molecular properties and biological 
functions of these apolipoproteins may identify a determinant of diabetic HTG in TH mice.    
Further, our long term study includes genetic characterization of HTG in TH mice.  The 
importance of genetic controls in lipid metabolism has been demonstrated through 
epidemiological studies illustrating that 30 to 45% of the phenotypic variance for lipid and 
lipoprotein phenotypes is accounted by genes whereas environmental factors account for less 
than 15% of the variance (80).  Therefore, genetic dissection of susceptibility genes accounting 
for the HTG in TH mice will provide important information for understanding the underlying 
molecular mechanism of HTG in this model. 
Knowing the pathophysiological mechanism and genes responsible for the HTG in TH 
mice will provide ready targets for lipid lowering therapy, ultimately preventing CHD, in T2DM 
patients.  This will also provide a new mouse model for T2DM with dyslipidemia that will be useful 
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Hepatic VLDL-TG production in vivo. 
 
1. Fast mice overnight. 
2. Weigh mice before injection. 
3. Inject intraperitoneally with 500 mg of Triton WR 1339; plasma VLDL clearance is completely 
inhibited under these conditions.  
Preparation of Triton WR 1339: 
1. Weigh out 100 mg of tyloxopol (about 3 drops). 
2. Load 0.9% NaCl (saline) up to 1 ml/1000 µl mark of 1.5 ml microcentrifuge. 
3. Mix by pipetting up and down. 
4. Collect blood via the retro-oribtal plexus at 0, 1, 2, 3, and 4 hour time points after the injection.  
5.  Centrifuge for 10 minutes at 4000 x g at 4ºC 
6. Determine plasma triglyceride levels by assay.  
 
 
[Next, 5 µl VLDL and 2 ml solvable were loaded into a disposable scintillation vial.  10 ml of 
scintillation fluid (Eco Lite) was then loaded into the vial and gently mixed.  One hour later, the 
VLDL levels were measured using the Beta Counter in disintegrations per minute (DPM).] PUT [ ] 
IN YOUR APPENDIX.   
Hepatic VLDL-TG clearance in vivo. 
Day 1: 
1. Inject 100 µl of [3H] palmitic acid into tail vein. 
Preparation of [3H] palmitic acid: 
1. Make 200 µl/200 ml for 20 mice. 
2. Working solution is 1mCi so 1 mCi/.85 (stock) = 1.17 ml 
3. For 20 mice, .117 ml x 20 = 2.34 ml 
4. Load 2.34 ml of [3H] palmitic acid into 15 ml tube. 
5. Evaporate ethanol by nitrogen gas (about 1.5 hours). 
6. Redissolved by loading 2 ml of 0.9% NaCl and 4 mg/ml of BSA powder into 15 ml 
tube. 
2. Do cardiac puncture (bled from the abdominal aorta) 25 minutes after injection. 
3. Centrifuge for 11 minutes at 1200 x g at 4ºC (until you see plasma). 
4. Load 2.4 µl of plasma and 9.6 ml NaCl and KBr solution to a 12 ml polyallomer centrifuge 
tubes.    
 Preparation of NaCl and KBr solution: 
1. Weigh out 15.3 g NaCl and dissolve into 100 ml sterilized deoionized water. 
2. Weigh out 35.4 g KBr and dissolve into 100 ml sterilized deoionized water.   
3. Need a final concentration of .65% and 1.52%. 
a. 15.3 x X = 0.65 x 100 = 65/15.3 = 4.25 ml NaCl 
b. 35.4 x X = 1.52 x 100 = 152/35.4 = 4.29 ml KBr 
c. Measure NaCl and KBr respectively and 0.9% NaCl is added to make the 
final concentration of 100 ml in a volumetric flask.   
d. A density < 1.019 is needed. 
1. Weight of the volumetric flask before: 61.49g 
2. Weight of the volumetric flask after: 163.01 g 
3. 163.01 – 61.49 = 101.52/100 = 1.0152 (density < 1.019) 
5. Ultracentrifuge plasma with NaCl and KBr solution for 16 hours at 40,000 x g at  









1. Slice the tube (using the tube slicer) and withdrawal liquid (VLDL) from the top portion 
(~1.5cm) of tube using a syringe or pipette.  Remove the sliced off portion of the tube and 
pull the blade out. 
 See directions using the Tube Slicer. 
2.  Measure 5 µl and 2 ml of solvable and load contents into a disposable scintillation vial.   
3.  Load 10 ml of scintillation fluid (Eco Lite) into a vial, mix and wait about 1 hour. 
4.  Count using the Beta-Counter in disintegrations per minute (DPM). 
5.  Inject 100 µl of radiolabeled VLDL into each fasted mouse (overnight).   
 Preparation of radiolabeled VLDL: 
  1.  Measure 1848 µl of 0.9% NaCl (saline) and 552 µl of VLDL. 
6.  Collect blood via the retro-oribtal plexus at 5, 10, 15, 20 minute time points after the injection.   
7.  Centrifuge for 10 minutes at 4000 x g at 4ºC.   
8.  Measure 10 µl of plasma and 4 ml of solvable and load into vial. 
9.  Load 10 ml of scintillation fluid into vial and allow to mix with the plasma.  
10.  Dissolve for a few minutes.   
11.  Count VLDL using Beta-Counter. 
 
 
Northern blot analysis  
 
Total RNA Extraction from liver tissue using the RNeasy Midi Kit (Qiagen, Valencia, CA). 
  
1. Homogenize frozen liver tissue in 10 ml tube with 6 ml of Buffer RLT and 60 µl of Beta-
Mercaptoethanol (B-ME).  Use under fume hood. 
2. Cap the tube securely and shake it by hand vigorously for 15 seconds. 
3. Centrifuge for 10 minutes at 3400 x g at 22ºC.   
4. Transfer the lysate to a new 15 ml test tube by pipetting. 
5. Load 6 ml of 70% ethanol in DEPC treated water to the lysate and mix immediately by 
shaking vigorously to avoid RNA contamination. 
6. Without delay, apply the sample to an RNeasy midi column placed in the 15 ml centrifuge 
tube (supplied). 
7. Close the tube gently. 
8. Centrifuge for 5 minutes at 3400 x g at 22ºC.   
9. Discard the flow-through. 
10. Repeat steps 6-9, using the remainder of the sample (up to 4 ml). 
11. Load 4 ml of Buffer RW1 to the RNeasy column. 
12. Close the tube gently.   
13. Centrifuge for 5 minutes at 3400 x g at 22ºC to wash the column.   
14. Discard the flow-through. 
15. Load 2.5 ml of Buffer RPE to the RNeasy column. 
16. Close the tube gently. 
17. Centrifuge for 2 minutes at 3400 x g at 22ºC. 
18. Discard the flow-through. 
19. Load another 2.5 ml of Buffer RPE to the RNeasy column. 
20. Close the tube gently. 
21. Centrifuge for 5 minutes at 3400 x g at 22ºC to dry the RNeasy silica-gel membrane 
22. Discard the flow-through. 
Note: it is important to ensure that the RNeasy membrane is dry since residual ethanol may 
interfere with downstream reactions. 
23. To elute, transfer the RNeasy column from the centrifuge tube very carefully to a new 
collection tube (supplied).  
24. Load 250 µl of RNase-free water directly onto the RNeasy silica-gel membrane. 
25. Close the tube gently. 
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26. Let it stand for 1 minute. 
27. Centrifuge for 3 minutes at 3400 x g at 22ºC. 
28. Do not discard. 
29. Repeat the elution step with a second volume (250 µl) of RNase-free water.  This wash 
the release more RNA. 
30. Load the RNA volume (500 µl) to a new microcentrifuge.   
31. Load 50 µl of Sodium Acetate 3M in DEPC treated water into the microcentrifuge.  
32. Vortex using the Type 16700 Mixer. 
33. Load 500 µl of isopropanol into the microcentrifuge. 
34. Invert microcentrifuge. 
35. Centrifuge for 20 minutes at 13000 x g at 4ºC. 
36. Carefully discard the solution and load 500 µl of 70 % ethanol in DEPC treated water into 
the microcentrifuge. 
37. Allow pellet to dry completely under fume hood for 5 minutes.  
38. Load 15 µl of RNase free water to the sample and vortex until is pellet is dissolved. 
39. Quick spin and vortex. 
40. Load 10 µl of formamide, 3.6 µl of formaldehyde, 2 µl of 10X Mops, 2.4 µl of RNase free 
water, and 2 µl of RNA into a new microcentrifuge.   
41. Store preparation into incubator for about 15 minutes. 
42. Store RNA at –80 ºC.   
43. After incubation, transfer microcentrifuge into ice chest for about 15 minutes. 




 Preparation of 1 % agarose/2.2M agarose gel: 
1. Weigh .5 g agarose. 
2. Mix agarose with 36 ml sterilized deionized water in a baked (autoclave) flask.  
3. Microwave until agarose is cooked (about 25 seconds). 
4. Remove flask from microwave and shake. 
5. Return flask to microwave and heat again (about 10 seconds). 
6. Cool gel solution in fume hood. 
7. Add 5 ml of 10X MOPS to gel solution. 
8. Add 9 ml of formaldehyde to gel solution and shake.  Formaldehyde is added to denature 
the RNA and make it run true to size. 
9.  Set up cast, making sure to add the comb (creates wells for the RNA). 
10. Pour gel solution into cast.   
11. Set until gelled (about 1 hour). 
12. Carefully pour buffer solution into the over the electrophoretic gel box trying to minimize 
bubbles. 
13. Remove comb. 
 
Preparation of samples to load on gel. 
1. Samples will have a final volume of 20 µl.   
2. Add 3 µl dye into each sample and load into wells. 
3. Run gel from negative to positive at 100 volts for 1 hour (times may vary).   
4. After running the gel, carefully transfer the gel into a plastic staining container. 
5. Pour deionized water (around 100 ml) over the gel. 
6. Load 5 µl of ethidium bromide into the plastic staining container. 
7. Stain for 10 minutes using lab rotator. 
8. Pour ethidium bromide waste into glass jar. 
9. Destain gel from 30 minutes to overnight by pouring deionized water over gel into the 
plastic container (about 2/3).   
10. Capture the image of the gel using the High Performance Ultra Illuminator.  
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 Directions using the High Performance Ultra Illuminator 
1. Carefully transfer the gel from container to High Performance Ultra Illuminator. 
2. Close door. 
3. Select Kodak 1DLE 3.5. 
4. Select Capture. 
5. Select SYBR Green. 
6. Select 20.5 x 28 cm. 
7. Select 3.5 sec. 
8. Select on. 
9. Take picture. 
10. When processing image, select off.  
11. Close. 
12. Save as Jpeg file. 
13. Image display. 
 
 Preparation of buffer for gel solution 
1. Load 25 ml of 10X MOPS to a baked cylinder. 
2. Mix with 225 ml of sterilized deionized water. 
3. Parafilm is used as a lid for the cylinder. 
4. Invert buffer solution. 
 
 Transfer to a Hybond N+ (membrane) (Amersham Piscataway, NJ). 
 
1. Take white plastic staining dish and fill with buffer solution containing 20 X SSC (about 
500 ml). 
2. Use yellow gel plate (medium sized gels) and turn upside down and place over staining 
dish perpendicularly. 
3. Make 2 long strips of Watmann paper.  They should be long enough to drape over the gel 
plate and into the 20 X SSC on both sides.  They should be wide enough to fit the size of 
the gel to be transferred and have some extra space on the top and bottom. 
4. Set a glass over the gel plate containing the buffer solution. 
5. Position the 2 long strips of Watmann paper over the glass—folding down the sides and 
making sure that wick is saturated in the buffer solution. 
6. Position the gel to be transferred flipped on the top of the papers and smooth out all air 
bubbles. 
7. Using saran wrap, cover all 4 sides of the papers, gel plate, and staining dish.  The only 
thing that should be left uncovered is the gel.   
8. Place the membrane on top of the gel and smooth out all air bubbles. 
9. Wet 2 pieces of the cut Whatmann paper with sterilized deoinozied water and place on 
top of the membrane (remove all air bubbles). 
10. Place 3 dry gel sized Whatmann papers on top of the wet ones. 
11. Stack 4.5 inches of folded white paper towels (cut in half) on top of the Whatmann papers.   
12. Place another glass over the white paper towels. 
13. Add a weight to the top of the glass.  Usually a Sigma catalog book is sufficient.  Make 
sure weight is balanced, so it does not fall over throughout the night.   
14. Set overnight. 
 
 Hybridize overnight with random primed α-32P-labeled Apo C-III cDNA probe. 
 
1. Next day uncover everything down to the membrane.  Be careful only to touch outside 
edges of the membrane. 
2. Poke holes in the membrane corresponding to each well on the gel.  Then carefully flip 
membrane over and cut the upper hand left corner.   
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3. Carefully place the membrane in a white weighing boat and use UV machine to expose 
the membrane for 2 minutes.   
4. Use a pencil and write what is in each lane on top of the membrane.   
5. Then wrap completely in saran wrap and store until ready to label.   
Directions on using the DNA transfer lamp: 
1. Select on. 
2. Open door. 
3. Slide in weighing boat containing the membrane. 
4. Set start: 2 minutes.  
Pre-hybridization 
1. Set hybridization oven at 65ºC. 
2. Place rapid hybridization buffer in the oven—warming until temperature reaches 65ºC 
(about 20 minutes). 
3. Place mesh (same size as membrane) and the membrane in a small boat containing 100 
ml of 2 X SSC. 
4. Add 7 ml of rapid hybridization buffer to a glass bottle. 
5. Roll membrane on top of mesh and carefully set in the glass bottle containing the rapid 
hybridization buffer.  Use large forceps and do not touch the inside of the membrane. 
6. Slowly unroll the membrane in the glass bottle, and eliminate air bubbles. 
7. Set bottle in hybridization oven from 2 hours to overnight.  
 
Rediprime II Random Prime Labeling System (Amersham). 
1. Mix 15 µl of APO C III probe and 33 µl of TE buffer into a new microcentrifuge.    
2. Denature the DNA sample by heating to 100 ºC for 5 minutes in heating block. 
3. Immediately place the DNA sample in ice chest for 5 minutes. 
4. Vortex and quick spin the contents. 
5. Add the denatured DNA (45 µl) to the rediprime (reaction tube). 
6. Add 5 µl of 32-phosphorous (32-P) to the rediprime. 
7. Gently agitate by flicking tube until solution is dissolved. 
8. Quick spin. 
9. Incubate at 37 ºC for 10 minutes. 
10. Stop the reaction by loading 5 µl of 0.2 M EDTA into the rediprime. 
11. Denature the labeled DNA by heating at 100 ºC for 5 minutes and then snap cool on ice 
for 5 minutes.   
12. Load 60 µl of DNA sample into the bottle. 
13. Place the bottle back in hybridization over overnight. 
 
 Wash blots 
1. Take bottle out of hybridization oven. 
2. Pour solution in waste (32-P) bucket.  Do everything in fume hood. 
3. Use forceps to remove the mesh and membrane out of bottle and transfer into large 
plastic container containing 2 X SSC/0.5% SDS (about 350 ml).  This is the first wash. 
Preparation of 2 X SSC/0.5% SDS: 100 ml of 20 X SSC + 5 ml SDS.   
4. Place plastic container in water bath (set at 65 ºC) for 20 minutes. 
5. Make sure to place weights over the container. 
6. Pour washing solution in sink, keeping both the mesh and membrane in container. 
7. Add .5 X SSC/0.5% SDS solution in the container.  This is the second wash.   
Preparation of .5 X SSC/0.5% SDS: 25 ml of 20 X SSC + 5 ml SDS). 
8. Place plastic container in water bath (set at 65 ºC) for 20 minutes. 
9. Make sure to place weights over the container. 
10. Pour washing solution in sink, keeping both the mesh and membrane in container. 
11. Add .1 X SSC/0.5% SDS solution in the container.  This is the third wash.   
Preparation of .5 X SSC/0.5% SDS: 5 ml of 20 X SSC + 5 ml SDS). 
12. Place plastic container in water bath (set at 65 ºC) for 20 minutes. 
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13. Make sure to place weights over the container. 
14. Pour washing solution in sink, keeping both the mesh and membrane in container. 
15. Remove membrane from container and lay over wick type paper for drying, but do 
not let membrane deep dry. 
16. Carefully wrap membrane in saran wrap. 
17. Place the membrane in audioradiography cassette (intensifying screen) and secure 
membrane by taping the bottom and top sides of the saran wrap.  
18. Place mesh in white paper towels. 
19. Take out the film box and bring to dark room along with the membrane enclosed in 
the audioradiography and intensifying screen.   
20. In dark room, place film in the screen and close.   
21. Store the audioradiography and intensifying screen in –80 ºC for 30 minutes to 
overnight (exposure times vary).  
22. Take screen out of –80 ºC storage and bring to dark room. 
23. Open screen and place film through the developer.   
24. When finished take film out.   
 
Instructions for operating the developer: 
Warming up: 
1. Close the wash water drainage valve, making sure that the developer and fixed 
drainage valves are closed. 
2. Turn on the power beaker on the right side of developer.  You will see the RUN 
button lamp goes on. 
3. Press the Run button.  The Run lamp will light up to indicate the SRX-101A is 
operation.  It will automatically go out if no film has been inserted for 8 hours. 
4. Close the feed tray cover. 
5. Wait for 20-30 minutes until the ready lamp lights up.  The SRX-101A is ready for film 
processing.  
Inserting film: 
1. Make sure that the Ready lamp is ON. 
2. Open the feed tray cover. 
3. Insert film, always lining up the film edge to either right or left guide located on the 
feed tray. 
4. After the leading edge of the film is grabbed by the roller, the film will be automatically 
fed into the developer. 
5. The ready lamp will go out. 
6. When a ready signal (beep) sounds and the ready lamp goes on again (10 sec) you 
can insert next film. 
Shutting down: 
1. Press the RUN button.  The run lamp will go out. 
2. Open the water drainage valve.  Leave the developer and fixer drainage valves 
closed.    
3. Open the feed tray cover to prevent condensation inside the main unit. 
4. Turn off the power breaker.    
 
Preparation of 20 X SSC in DEPC treated water  
15. Mix 175 g of sodium chloride (NaCl) and 8 g of sodium citrate (Na3 citrate) in 1000 ml of 




Total RNA Extraction by RNeasy Midi Kit (Qiagen, Valencia, CA) for real time RT PCR. 
 
1. Homogenize frozen adipose tissue in 50 ml tube with 15 ml QIAzol Lysis Reagent. 
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2. Place the tube containing the homogenate on the benchtop at room temperature (25ºC) for 5 
minutes. 
3. Add 15 ml Chloroform, cap the tube securely and shake it by hand vigorously for 15 seconds 
to extract excess lipids. 
4. Place the tube containing the homogenate on the benchtop at room temperature (25ºC) for 
2-3 minutes. 
5. Centrifuge at 3400 x g for 20 minutes at 4ºC.   
6. Transfer upper aqueous phase to a new 15 ml tube.   
7. Add an equal volume of step 6 of 70% ethanol, and mix thoroughly by vortexing.  Do not 
centrifuge.  Continue without delay. 
8. Pipet up to 4 ml of the sample into an RNeasy Midi Spin Column in a 15 ml collection tube 
(supplied).  Close the tube gently. 
9. Centrifuge for 5 minutes at 3400 x g at 25ºC.   
10. Discard the flow-through. 
11. Repeat steps 8-10, using the remainder of the sample (up to 4 ml).   
12. Add 4 ml Buffer RW1 to the RNeasy Midi Spin Column.  Close the tube gently. 
13. Centrifuge for 5 minutes at 3400 x g at 25ºC to wash the column.   
14. Discard the flow-through. 
15. Add 2.5 ml Buffer RPE to the RNeasy Spin Column.  Close the tube gently. 
16. Centrifuge for 2 minutes at 3400 x g at 25ºC to wash the column.  
17. Discard the flow-through. 
Note: Buffer RPE is supplied as a concentrate.  Make sure that 95% ethanol is added to Buffer 
RPE before use. 
18. Add another 2.5 ml Buffer RPE to the RNeasy Spin Column.  Close the tube gently. 
19. Centrifuge for 5 minutes at 3400 x g at 25ºC to dry the RNeasy silica-gel membrane.   
Note: It is important to dry the RNeasy silica-gel membrane since residual ethanol may interfere 
with downstream reactions.  This step ensures that no ethanol is carried over during elution.   
20. Carefully remove the RNeasy Midi Spin from the collection tube so the column does not 
contact the flow through as this will result in carryover of ethanol.   
21. To elute, transfer the RNeasy Midi Spin Column to a new 15 ml collection (supplied).   
22. Pipet 100 µl of RNase free water directly onto the RNeasy silica-gel membrane.  Close the 
tube gently.  
23. Let the tube stand for 1 minute. 
24. Centrifuge for 3 minutes at 3400 x g at 22ºC 
25. Repeat steps 22-24.  Elute into the same collection tube.  This wash will release more RNA. 
26. After centrifugation, pipet the 200 µl to a new microcentrifuge.   
27. Add 20 µl of Sodium Acetate 3M in DEPC treated water into the solution. 
28. Vortex the microcentrifuge using the Type 16700 Mixer.   
29. Add 200 µl of isopropanol into the microcentrifuge.   
30. Invert the microcentrifuge. 
31. Centrifuge at 13,000 x g at 4ºC for 20 minutes.   
32. After centrifugation, a pellet should form.  Carefully discard the supernatant solution onto kim 
wipes. 
33. Re-suspend pellet in 200 µl of 70% ethanol in DEPC treated water into the microcentrifuge.   
34. Carefully close the lid and vortex. 
35. Centrifuge at 13,000 x g at 4ºC for 10 minutes. 
36. Discard the solution and allow pellet to dry completely under fume hood for 5 minutes. 
37. Re-suspend pellet in 10 µl of RNase-free water into the microcentrifuge. 
38. Vortex until pellet is dissolved.   
 
 
Quantification of RNA by Nano-drop (ND) 
 
1. On the computer, select ND-1000 program. 
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2. Select nucleic acid. 
3. Load 1 µl of DEPC treated water onto ND to initiate.   
4. Select OK. 
5. Change the program to RNA-40.   
6. Pull the handle down.   
7. Clean the ND with kim wipe. 
8. Select blank. 
9. Pull the handle down.  
10. Type in sample ID. 
11. Flick tube with sample. 
12. Load 1 µl of RNA to ND.   
13. Pull handle down. 
14. Select measure.   
15. Print report and exit.   
 
RNA →→ cDNA 
 
1. Load 2 µg RNA and RNase free water to add up to 12 µg concentration to 1.5 ml tube. 
2. Load 2 µl oligo dT primer into tube with RNA and RNase free water.   
3. Load 2 µg RNA of each sample to reference tube with RNase free water.  
4. Gently tap tube to vortex. 
5. Turn on PCR machine. 
6. Select program. 
7. Select list: cDNA. 
8. Close lids of PCR machine. 
9. Run PCR machine at 70 ºC for 10 minutes. 
10. Pause at 70 ºC. 
11. Immediately set samples on ice for 1 minute. 
12. Prepare reagents while samples are in PCR machine.  
13. Spin down reagents.   
14. Load 1 µl of dNTPs, 2 µl of 0.1 M DTT, 4 µl of 5 X buffer synthesis, and 1 µl of SSII RT 
(superscript enzyme) into new 1.5 ml tube.   
15. Gently tap tube to vortex. 
16. Add reagents to RNA tube.   
17. Gently tap tube to vortex. 
18. Close lids of PCR machine. 
19. Resume PCR machine (select pause) at 25 ºC for 10 minutes, 42ºC for 50 minutes, and 
70ºC for 15 minutes. 
20. Immediately set samples on ice for 1 minute. 
21. Load 20 µl of prepared samples into new 1.5 ml tube.  
22. Store cDNA at -20 ºC for short term.   
 
 
cDNA for RT real time PCR: 
 
Dilutions: 
1.  Add 20 µl of RNAase free water to each tube (5 total). 
2.  Add 5 µl of cDNA to tube #1.   
3.  Transfer 1 µl solution from tube #1 to tube #2.  Flick. 
4.  Transfer 1 µl solution from tube #2 to tube #3.  Flick 
5.  Transfer 1 µl solution from tube #3 to tube #4.  Flick 
6. Transfer 1 µl solution from tube #4 to tube #5.  Flick 
 
1.  Add 1 µl of diluted cDNA into each sample tube. 
 60
2.  Add 10.5 µl of RNAase free water into each tube. 
3.  Add 1 µl of RT2  PCR Primer Set (LPL, 18S-Super Array) into each tube. 
4.  Add 12.5 µl of RT PCR Master Mix into each tube. 
5.  Add 25 µl solution from each tube into each well of the Thermo-Fast 96 Detection Plate 
(catalog # AB-1307)  
6.  Using the Adhesive Seal Applicator (part # 436 5988 AB) drape optical adhesive cover (part # 
431197 AB) over well plate.   
7.  Place well plate into computer to begin RT Real Time PCR. 
 
Set-up 
Well Inspector  
Use Detector Reporter Quencher Task Quantity Color 
Check LPL/18S SYBR None Unknown Blank Black  
 
Passive Reference: ROX 
To Generate Standard Curve 
Use Detector Reporter Quencher Task Quantity Color 
Check LPL/18S SYBR None Standard 625 Black  
Use Detector Reporter Quencher Task Quantity Color 
Check LPL/18S SYBR None Standard 125 Black  
Use Detector Reporter Quencher Task Quantity Color 
Check LPL/18S SYBR None Standard 25 Black  
Use Detector Reporter Quencher Task Quantity Color 
Check LPL/18S SYBR None Standard 5 Black  
Use Detector Reporter Quencher Task Quantity Color 
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1. Turn machine on. 
2. Press 1. 
3. Set up test and select 3 for wavelength.  Read glucose at 500 nm and triglyceride at 540 nm.  
4. Select enter and 3 again. 
5. Place deoionized water reference in #1 well.  Make sure the arrow on the cuvet is pointing left. 
(7 cuvettes total; order: water, then standard, then duplicate. 
6. Select cell down, B-blank 
7. Auto zero (to change wavelengths).   
8. Cell up-well #2. 
9. Select measure. 
10. Select measure again. 
11. Discard cuvettes after reading absorbencies 
 
GLUCOSE ASSAY  
 
1. Prepare the glucose reagent if necessary; load 50 ml of sterile deoionized water into cylinder 
to make up solution.   
2. Set up enough cuvettes for standards and samples, include duplicates of each. 
3. Load 900 µl of glucose reagent to each cuvet, including standards (0 mg/dl: water blank, 25 
mg/dl, 50 mg/dl, 75 mg/dl, and 100 mg/dl) and samples.   
A.  For the standard cuvettes, do not dilute; using M10 pipette, load 6 µl of standard to 
cuvettes; wash tip of pipette after each time, including duplicates; quick spin and vortex the 
standards before use. 
B. For the sample cuvettes (and duplicates): dilute; using M10 pipette, load 4 µl of 
sterilized deoionized water to cuvet; next load 2 µl of plasma to each cuvet; do not 
forget to wash tip of pipette.   
4. Vortex all cuvettes.   
5. Allow cuvettes to incubate for 10-15 minutes at room temperature.   




1. Prepare the Free Glycerol Reagent and the Triglyceride (TG) Reagent according to the 
preparation instructions 
A. Free Glycerol is 40 ml; TG reagent is 10 ml. 
2. Warm up the spectrometer and set it to read OD of 540 nm and auto zero with water. 
3. Warm up the Free Glycerol Reagent to room temp before starting the assay (all reagents 
need to be kept in -20 ºC when not in use).   
4. Set up enough cuvettes for a blank, standards, and all samples.  No duplicates for samples 
5. Load 640 µl of the Free Glycerol Reagent into each cuvet-set epindorf to 2 (this is 500 µL); 
for the rest of the 640 µl, load 140 µl into the cuvettes using the blue tips. 
6. Load 8 µl of water to the blank, 8 µl of the 250 mg glycerol standard to one cuvet and 8 µl of 
the 500 mg glycerol standard to the other standard cuvet; load 8 µl of plasma (from samples) 
to cuvettes; use M10 (red pipette).   
7. Vortex samples, and allow to incubate for 10-15 minutes at room temperature. 
8. Read and record the initial absorbance (IA) of the blank, standards, and samples versus 
water as the reference (just add deionized water to a random cuvet). 
9. Load 160 µl of the TG reagent into each cuvet, vortex, and incubate at room temperature for 
10-15 minutes. 
 62
10. Read and record absorbance (FA) of blank, standards, and samples versus water as the 
reference.   




1. Add 200 µl of sterile deoinized water to first well. 
2. Add 200 µl of reagent (standard-Infinity Cholesterol) to second well. 
3. Add 200 µl of reagent (std) + 2µl of sterile deoinized water to third well. 
4. Add 200 µL of reagent (std) + 2 µl of sample to fourth well. 
5. Then load all samples to wells- 2 µl.   
6. No duplicates. 
7. Allow to incubate at room temperature—drape a kim wipe over it. 






1. White towel on lab bench 
2. Close window when opening buffer-powder 
3. Add buffer into I-125 
4. Make waste bags (2)—throw away buffer into waste bag 
5. Fold down over 2nd bag 
6. Leave I-125 in hood 
 
Keep samples on ice 
7. Label tubes—samples beginning with tube #25 
4 samples (#25, 27, 29, 31) duplicates or no duplicates 
 
1. Label tubes (standards 1-24) (no duplicates) 
2. Add to sample tubes first: 25 µL buffer into sample tubes (using repeating pipette), then add 
25 µL of each sample to tube, using L100 pipette.  Start with tube #25.  Place sample into 
tube; flick tube by hand—mixing tube, do not vortex, then pipette into tube.   
3. Step 1 pg 10 
a. 1, 2 blank; 3 and 4 add buffer assay, 100 µL; 5 & 6 add buffer assay, 50 µL; leave everything 
else blank. 
b. Steps 2 & 3; do what it says leave 1-6 blank; 7 thru 24-50 µL of reagent 
Make sure to hit the wall of tube with pipette. 
Everything can be done at bench. 
 
In hood. 
1. Step 4: Set epindorf to 1—I 125 Insulin tracer (red solution); add 50 µL to all tubes; 1 push 
(std + samples) just follow directions (no. 1-4); throw away tube (on epindorf using bag as a 
glove or use kim wipes) 
2. Step 5: add 50 µL of insulin AB starting with tube 5 (blue solution). 
3. Step 6: Vortex two tubes at a time.  Cover with aluminum foil and put radioactive label on top.  
And write I-125 using black marker. Incubate at 4 degrees; put labels on fridge too.  Incubate 




1. Remove samples from fridge (incubation) 
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2. Using epindorf (set to 2) add precipitating reagent-0.5 mL (green soln) to tubes; don’t do 
anything to tubes 1 and 2.   
3. Vortex all tubes (~5 sec) 
4. Get centrifuge ready. 
a. If needed, 6 min at 500 RPM for 4 degrees.  Press green button. 
b. Make sure yellow racks fit in machine (1 rack can hold 37 tubes) 
5. Take yellow racks to hood (prepare here for centrifuging) 
6. Landmark numbers on top.  Start with tube #3.  Leave 1 and 2 out.   
7. Carefully place samples in yellow rack.   
8. Need a Balance? 
a. 650 µL of tap water for balance 
9. Centrifuge samples at 3000 RPM for 21 minutes at 4 degrees. Press start. 
 
While centrifuging: 
10. Prepare to decant the supernatant (the soln on top); you want to see the pellet on bottom 
a. White towels 
b. Add kim wipes (~20-30) 
11. Remove samples when finished centrifuging.  Don’t disturb. 
12. Place samples (in order) into rack (day 2 rack-rack holds 90 samples); start in 2nd row 
13. Flip (invert) rack over slowly 
14. Fold over the 1st white towel and lay rack on top of it 
15. Use kim wipes to transfer tubes into other rack (rack that was used in day 1). Carefully 
wipe tube with kim wipe  
--if pellet is on side of tube, something went wrong. 
16. Throw away white towel (with solution) into waste bag. 
17. Computer (reading) 
a. Use machine on the right (w/ comp)—this is gamma. 
18. Place tubes in order (remember samples read backwards) into gray rack. 
19. On the 15th tube—slide #2 protocol into this tube; this is the 1st rack 
20. Place all racks (in order) into/over dent—underneath computer. 




c. Make sure Power is ON 
d. Make sure On Line is green  
e. If can’t read (someone is using machine, etc) leave samples covered in hood 
23. Clean up-wash rack with water in radiation sink 
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